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Abstract 
Prescribing Practice at a Tertiary Level Paediatric Hospital in South Africa 
 
Introduction: Prescribing for paediatric patients can be challenging for any prescriber. There are 
few studies on prescribing practice in paediatrics compared to that of adults. The paediatric 
population is usually excluded in clinical trials at the time when the actual medicines are 
developed. Thus the outcome of medicine use in the paediatric population can result in adverse 
events when rational use of medicine is not practiced by the prescribers. This motivated the 
researcher to embark on a study that focused on prescribing practice at RCWMCH. 
Objectives: The objectives of the present study were to describe the type and frequency of 
prescribing errors and error frequency, to determine the error frequency for different drug 
classes, to identify potential drug interactions and drug-disease interactions to point out off-label 
prescribing and to evaluate risk factors of prescribing errors. 
Methods: This prospective cross sectional study was conducted over a period of 6 months from 
July 2012 to December 2012 in 2 specialist wards and 2 general medical wards at Red Cross War 
Memorial Children’s Hospital in Cape Town in South Africa. Only prescriptions generated by 
doctors in the above mentioned wards were assessed. Convenience sampling was used to select 
200 prescription charts for analysis. Information relating to prescribing error, potential drug 
interaction, potential drug-disease interactions, off-label prescribing and potential risk factors of 
prescribing error were entered into excel spreadsheet and analysed using STATA versions 
11&12. The mass of the patients was converted into weight-for-age z-score (WAZ) using WHO 
2006 child growth standards. Univariate analysis and multiple logistic regression were used to 
identify risk factors of prescribing errors. 
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Results: Of the 200 children on whom prescribing information was analysed, 40 ( 20%) were 
severely underweight and a further 25(12.5%) were moderately underweight. A total of 1402 
prescribing errors were documented in 1282 drug items prescribed, a rate of 1.09 errors per drug 
item prescribed. Incomplete prescription information was the most common type of prescribing 
error, present in 65.6% of all drug items prescribed. The error frequency was high for all drug 
classes ranging from 57.9% of all respiratory drug items prescribed to 86.4% of all gastro 
intestinal  system drug items prescribed. The number of potential drug-drug interactions was low 
i.e. 20 potential pharmacodynamic  and  49 potential pharmacokinetic drug interactions were 
identified. The number of potential drug-disease interactions was also low i.e. 39 or 0.03% per 
drug item prescribed. Furthermore 57 off-label prescribing incidences were recorded. Senior 
doctors posed a significant risk factor for prescribing errors, an OR 1.95, 95% CI 1.46 – 2.61. 
Conversely, prescriptions written up in the general wards compared to the speciality wards ( an 
OR 0.65. 95% CI 0.47-0.90) and prescribing during weekends compared to weekdays ( an OR 
0.71, 95% CI 0.53-0.96) were associated with lower  prescribing error risk. 
Conclusion: This study provided valuable information about prescribing practices in children at 
RCWMCH. There is a need to improve prescribers’ practice  at RCWMCH considering the type 
of errors observed viz. missing information, use of wrong drug name, abbreviations, legibility 
concerns and lack of clarity of the prescriptions, among others. Based on this study results 
further intervention studies are recommended to investigate the level of medical student’s 
training w.r.t prescribing practice.  
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Chapter 1 
Introduction 
 
“Quality healthcare is not negotiable” (Van Zyl, 2011). This was the opening remark of the 
chairman of the Council for Health Service Accreditation of Southern Africa (COHSASA), 
made at the launch of the Safecare Initiative Conference in Cape Town in March 2011. 
Unfortunately, in the developing world, quality healthcare appears to be the exception rather 
than the norm. Interestingly, according to the World Health Organization (WHO), one of the 
ten main domains for concerns regarding healthcare in developing countries is preventable 
adverse drug events. Thanushya Pillay (2011), president of the South African Hospital and 
Institutional Pharmacists (SAAHIP), notes that pharmacists in India form an integral part of 
the healthcare team at the ward level in hospitals and are also involved in drug selection at 
the point of prescribing, almost serving in the role of “consultant”. The argument, then, which 
this thesis is concerned with, is: is it not perhaps time for South African pharmacists to 
become custodians of medicine in the true sense of the word as part of the healthcare team, 
serving in an advisory capacity with regards to all aspects of the prescribing of medication? 
 
1.1 Prescribing practice 
Prescribing of medication is one of the most common interventions used to treat patients. 
Prescribing is a doctor’s written direction (order) for the preparation, compounding and 
administration of a medicine. While it is commonly believed that practice makes perfect, the 
same, however, cannot be said about the prescribing practice in pharmacy. Moreover, 
prescribing for a paediatric population can be more of a challenge than for adults, and since 
there are very few available studies on prescribing practice in paediatrics compared to that of 
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adults, a study of this nature was undertaken towards the Master’s degree to assist in 
discovering the concerns and challenges experienced by prescribers, in general, and more 
specifically, with regard to children in South Africa. Good prescribing is not an easy 
discipline to master as prescribers are not necessarily trained to write prescriptions. Junior 
doctors, who generally have less practical experience with paediatric patients, are expected, 
at times, to prescribe without the necessary supervision from the senior doctors. 
 Unnecessary prescribing or over prescribing is not an uncommon practice, 
especially when doctors with less experience in healthcare of children are faced with the 
challenge of prescribing. As part of this Master’s study, a memorandum on correct 
prescribing practice was developed by the pharmacists involved and forwarded by hospital 
management to different departments at the Red Cross War Memorial Children’s Hospital 
(RCWMCH) in November 2013. Standard clear instructions about who may write and sign a 
prescription, emphasis on legibility, process regarding alteration of an item, and particulars 
about what must appear on a prescription, for example, prescriber and patient details and 
prescribed medicine details, were specified in the memorandum. Whilst on ward rounds 
during the undertaking of the research in real time, it became quite apparent that most 
prescribers failed to follow or read the memorandum detailing correct prescribing. This 
finding clearly highlighted an area of concern regarding prescribing practice, both in terms of 
junior and senior prescribers, prescribing practice referring to the lack of prescribing 
knowledge, be it the style of writing or in the decision-making process of prescribing. Thus, 
in the current study, it became a point of interest to know whether prescribing practice at  the 
RCWMCH influences the prescribing error rate, potential drug-drug interactions (DDIs), and 
potential drug-induced diseases drug-disease interactions  (DDiS), as well off-label (OL) 
prescribing.  
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 An assumption can and was made at the outset of this study that prescribing 
practice has become habitual (whether good or bad is beside the point) at times, with 
prescribers knowingly or un-knowingly prescribing medicines that interact with one another, 
not always considering the disease state of the patient,  and also in some cases prescribing 
medicines classified as off-label. Moreover, the increasing number of new medications 
released into the market is a major challenge for physicians. Additionally numerous studies 
have found that pharmacists can improve patient safety and outcomes by preventing adverse 
events by recommending optimal therapies and dosages (see, for example, Bond et al.,1999; 
Kaboli et al., 2006). Recently, all operational departments at teaching hospitals in Cape 
Town, South Africa, were audited by assessors as part of the National Core Standard audit in 
2011; although the overall outcome of the audit was outstanding, one area of the medication 
management system was criticized—the prescribing habits of physicians, thus confirming the 
need for intervention by pharmacists at the ward level. It is thus necessary that prescribers 
reassess their prescribing habits in light of our present social and economic circumstances in 
South Africa, that is, with the view of instituting more rational drug prescribing and reducing 
medicine usage to effect a favourable outcome. Prescribers must avail themselves of easily 
accessible information regarding good prescribing practice, which, in the long-term, will 
enhance drug therapy and reduce the incidence of adverse drug events due to inappropriate or 
incorrect prescribing. 
 
 
1.2 Prescribing errors 
It is a known fact that prescribing errors contribute majorly to medication errors in the 
medication management system, with prescribing for children a big challenge for any 
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prescriber in any healthcare setting. The need for calculations, dilutions, and manipulations of 
paediatric medicines, together with the need to dose on an individual patient basis taking into 
account age, gestational age, weight, and body surface area means that children are more 
prone to the effects of medication errors (Conroy, 2007). Moreover, prescribing is a high 
volume activity, meaning that even a small percentage of errors can lead to scores of serious 
adverse events (Conroy, 2007). 
Although the main theme of this thesis will focus on prescribing errors, potential 
drug-drug interactions (DDIs) and drug-disease interaction (DDiS), off-label (OL) 
prescribing will also be looked at in order to reveal and highlight concerns relating to 
prescribing practice at paediatric tertiary hospitals, such as RCWMCH, the site of this study. 
Error reporting is becoming common practice in some parts of the world, but, 
unfortunately, healthcare professionals in South Africa generally fail to report medication 
errors, let alone prescribing errors. This lack  or non- reporting of errors means that managing 
prescribing errors is virtually non-existent in the country. Yet, prescribing errors are 
potentially tragic and costly both in human and economic terms for patients and professionals 
alike (Cohen, 2000). For example, failure to standardize prescribing terms often leads to 
inappropriate use of dangerous abbreviations, acronyms, and coined names, thus enabling the 
easy misinterpretation of prescribing information (Cohen, 2000). However, research studies 
on interventions by pharmacists with regard to phramacovigilance in the healthcare system 
suggest that many medication errors occur and that clinical intervention by pharmacists helps 
to prevent adverse drug events (see, for example, Guy, 2003; Barber, 1997). 
Teaching hospitals in South Africa have for many years been the training ground for 
many a healthcare professional, including those from other parts of the world, with 
deleted)RCWMCH no exception in this regard. RCWMCH is one of very few paediatric 
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referral hospitals in Africa and, at any given time, has an interesting patient population that 
varies in age and co-morbid disease(s). This, coupled with the practice of poly-pharmacy and 
off-label prescribing, makes it the ideal place to monitor, detect, evaluate, and report 
prescribing errors. Currently, there are no clinical interventions and prescribing error 
reporting mechanisms by pharmacists at the ward level at RCWMCH, an indication that the 
skills and knowledge possessed by pharmacists are not being fully utilized with regard to 
pharmacovigilance.  
      
1.3 Factors influencing prescribing 
Clinical training of medical students focuses more on the theory than the practice of 
pharmacology. As a result, most medical students remain unsure about the actual 
requirements, methods and best practice of prescribing, that is, how to actually prescribe. To 
begin with, pharmacology reference books, drug-centered and clinical textbooks rarely 
discuss therapeutic recommendations, that is, they do not discuss why certain therapies are 
chosen and so forth, thus leaving the potential prescriber to figure out on his or her own the 
therapeutic drug regimen for the underlying condition (de Vries et al.,1994).  
Moreover, prescribing is influenced by such factors as effectiveness and harm of a 
medicine, external influences, and cognitive biases. The poor choice of a medicine, poly-
pharmacy, co-prescribing of potentially interacting drugs, prescribing for a self-limiting 
condition, and continuing to prescribe for a period longer than is necessary are a few of the 
factors contributing to irrational prescribing. Irrational prescribing influences morbidity and 
mortality, especially in the treatment of childhood infections or chronic diseases, such as 
hypertension, diabetes, epilepsy, and mental disorders. Irrational or incorrect prescribing can 
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affect public health at large; for instance, in the case of antimicrobials, resistance can result 
from irrational prescribing, especially in children.  
The procurement and prescribing of pharmaceuticals, both important chains in the 
medicine management system, are governed by various guidelines. Such guidelines are 
critical for sustaining medicine stocks for patient care at RCWMCH. The Standard Treatment 
Guidelines (STG) for paediatrics, Western Cape (PGWC) code list, the National department 
of Health (NDoH) tenders, the Pharmacy and Therapeutics Committee, and the PGWC 
procurement policies all provide guidelines in this regard. There are many challenges in 
maintaining adequate stock levels of pharmaceuticals as a result of the above guidelines; in 
addition, formularies and the various guidelines are not aligned with each other, thus 
influencing prescribing directly or indirectly. To start with, not all medicines on the PGWC 
code list are on the NDoH tenders, which results in a medicine needing to be procured as a 
buy-out. Secondly, NDoH tenders are renewed every two years and often medicines on the 
PGWC code list are removed from the tender. This then necessitates a change in the code list, 
affecting both procurement and prescribing. Thirdly, paediatric formulations of medicines are 
often not placed on the NDoH tenders but incorporated in the STG. In addition, prescribers 
do not necessarily refer to all these guidelines. There are other factors too, such as newly 
recruited health professionals from the private sector, foreign doctors, and experienced 
doctors (used to certain treatment regimens) who are each comfortable in prescribing in 
accordance with very different and personal styles. Pharmaceutical companies also influence 
prescribers, with teaching hospitals not excluded from this tendency, especially as concerns 
the use of new or existing drugs in certain drug trials. The prescriber, in such cases, is obliged 
to prescribe the medication during the trial period in lieu of certain incentives provided by the 
drug company to the prescriber. Certain drugs are no longer registered in South Africa 
(Section 21 drugs) and are not easily obtainable, resulting in patients not receiving the 
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intended drug on time or even not at all. Prescribers are then obliged to search for alternatives 
to the requested drug; sometimes, such alternatives are        non -existent. 
 
1.4 Possible determinants or predictors of prescribing errors 
A study in 1998 on drug related problems at Addington Hospital by Moodley (2000) South 
Africa focused on geriatric patients. According to the study, the most common prescription 
interventions centered on problems involving drug therapy monitoring, safety of drug 
therapy, indication of drug therapy, prescribing errors, prescription information and omission. 
The  study at RCWMCH focuses on the type of prescribing errors due to the prescribing 
practices of doctors, where, amongst others, age, poly-pharmacy and off label prescribing act 
as possible contributing risk factors associated with potential prescribing errors. Possible 
determinants or predictors of prescribing errors included: level of qualification of the 
prescriber (that is, senior versus junior doctor status), day of the week the item was 
prescribed, age of the patient (in terms of infant and child groups), location of the ward (that 
is, specialty versus general medical wards), drug formulation, class of the drug, number of 
drugs prescribed and formulary status of a drug. All these possible determinants have a direct 
influence on the prescriber, thus contributing to potential errors. 
Chapter 2, following, on reviewing the literature  will cover topics related to the main 
theme of study, namely, prescribing errors, drug-drug interactions (DDIs), drug-disease 
interactions (DDiS) and off label (OL) prescribing. It will also present the study’s research 
question and hypothesis with regard to adherence of prescribers to the Medicines and Related 
substance Act 101 of 1965 (Medicines and Related Substance Act101 of 1965, Regulations as 
amended,2014:28) The aims and objectives are also outlined, providing the focus on type of 
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prescribing errors, error frequency per different classes, potential drug interactions, drug-
disease interactions off label prescribing and determinants of prescribing errors.  
Chapter 3 concentrates on the materials and method used and outlines the study 
design, site and population, inclusion and exclusion criteria, sample size, parameters assessed 
and definitions of the type of prescribing errors. In addition, drug-drug interactions, drug-
disease interactions and off label prescribing are explained in terms of types of parameters, 
respectively. Nutritional status is also defined in terms of weight for age for the study 
population. The methods of statistical analysis are explained in this chapter as well as the 
timeframe and ethic consideration as per the different institutions. 
Chapter 4 presents the results of the study, including the sample size, age distribution, 
and the presenting conditions of the patients in the study. The results are presented in tabular 
form, with 31 tables provided. Each table succinctly describes the legends contextually, with 
a brief description of the contents of the respective tables provided as a footnote.  
Chapter 5 discusses the findings as reflected in Chapter 4, namely the results. The 
findings of other similar studies are also discussed and comparisons are made between the 
findings of the present study at RCWMCH and those conducted in other parts of the world. 
Chapter 6, summarizes and discusses key points, anomalies and essentially contextualizes 
the study in terms of its wider relevance, that is, beyond the site of study at RCWMCH. 
Recommendations with regard to limitations noticed or aspects needing further research are 
discussed.  
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Chapter 2 
Literature Review 
2.1 Introduction 
In this chapter, literature review will be presented on the topic of prescribing errors, which 
will be covered in sections 2.2. to 2.6. This will be followed by an outline of the parameters 
of the study introducing the research question, hypothesis, aim and objectives and potential 
value of the study. 
The focus of this literature review was the following:  (a) to highlight themes covered 
in the thesis, namely, prescribing errors, drug-drug interactions (DDIs), drug-disease 
interactions (DDiS) and off-label (OL) prescribing, and (b) to help address the research 
question (see 2.7.2 page 47, chapter 2)  The review focused on key paediatric research 
findings in relation to the research findings at RCWMCH.The literature review covers, in 
particular, the central theme of this study, namely, prescribing errors while also focusing on 
drug-drug interactions, drug-disease intteractions and off label prescribing as possible co-
factors in prescribing errors. Most of the literature search was accomplished digitally through 
electronic databases, including Science Direct, Ebsco Host search and references of reviewed 
articles searched from useful sources (that is, ACADEMIC SEARCH, CINAHL, HEALTH 
and MEDLINE). Search terms included “prescribing error”, “paediatric population”, “drug-
drug interaction”, “drug-disease interactions” and “off-label”. Hand searching of locally 
published journals was also undertaken to identify studies located in South Africa. A total of 
201 articles published between   1980 and 2013 were retrieved overall. 
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2.2 Paediatric population 
Children are not small adults and thus pose a challenge to any prescriber, be it a senior or a 
junior doctor. Children, especially the very young (infants), have immature organ systems; 
thus the effect of drugs on them is of major concern, with potential harm caused by medicines 
if these are not prescribed and administered in the correct manner. 
Growth assessment and nutritional status are important indicators of child health. The 
significance of detecting poor growth in early life is reflected in poor cognitive function and 
educational performance, and when accompanied by excessive weight gain later in 
childhood, increases risk of nutritional-related chronic diseases (Victora et al., 2008). In 
2004, child growth monitoring practices worldwide were reported as part of the construction 
of the WHO standards. Growth charts are since widely used in paediatric care and weight-
for-age has been adopted almost universally, followed by length/height-for-age and weight-
for-length/height (de Onis et al, 2006).  
Under-nutrition in childhood is one of the main contributing factors to high mortality 
rates in developing countries. A study carried out in 2012 in a slum in the state of Uttar 
Pradesh in India (Srivasta et al., 2012), assessed the influence of nutritional status on the 
health outcome of children aged 5 to 15. In the study, underweight (weight-for-age z-scores 
less than -2.00) reflected chronic and acute under-nutrition. It is important to note that 
nutritional status in children reflects the socio-economic status of the family, and in turn, the 
social well-being of the community and the health care system in general.  
 
Children are subjected to many of the same diseases that adults suffer from and are 
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often treated with the same drugs used to treat adults. However, many drugs used in children 
are not licensed for use in them or are prescribed outside the terms of the license, that is, they 
are used “off label”. The consequence of this practice, which is very common, can place 
children more at risk with regard to potential adverse drug events. Data needed for effective 
and safe drug treatment cannot be linearly abstracted from adult data and specific research is 
necessary. Unfortunately, obstacles for the conducting of research among children are many, 
including issues of a financial, ethical, scientific and practical nature. In order to further 
progress in paediatric research, rules and requirements in this research area need adjustment. 
An important step was taken by the European Commission (EU) on 28 September 2004 in 
adopting a proposal for the regulation on medicinal products for paediatric use. This proposal 
aims to improve the health of children in Europe by increasing research, development, and 
authorization of medicines for use in children. (Masoli et al., 2004) 
The benefits of the findings of future studies among children, as per the above 
proposal, may influence the way prescribing is practiced for the paediatric population not 
only in Europe but globally. Nonetheless, there is a need for ongoing studies to be conducted 
among children in both developed and developing countries. However, challenges in 
developing countries, including South Africa, are many, including limited resources, funding 
constraints and, perhaps, most importantly, obtaining the permission of caregivers to enroll 
their children as participants in research studies. There are many barriers to efficiently reduce 
the burden of disease in childhood. 
Such barriers include poverty, poor education, poor infrastructure, inherent barriers in the 
organization of healthcare services in terms of geography, type of professional responding, 
education and training systems, public and private care and the tendency of care to be “acute” 
rather than “routine”. It is common practice for prescribers and pharmacists to make educated 
guesses and to rely solely on their individual clinical experience when it comes to the issue of 
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prescribing. However, decisions regarding the safety and efficacy of medicines need to be 
considered with more efficiency because, in the first place, sufficient data is not available for 
children. Very often clinical decisions made by prescribers are based on the extrapolation of 
empirical data from studies on adults. This kind of practice is continued in clinical settings 
despite the fact that large differences exist between adults and children, even among children 
themselves (Masoli et al., 2004)  
Proper use of medicines among children is critical. Infectious diseases are one of the 
leading causes of deaths in children despite the availability of various vaccines and 
treatments for different infectious diseases. Indeed, one can question the accurate use of 
existing medicines and vaccines since current experience shows a crucial need to train and 
educate public health officials, physicians, and parents in the correct use of available vaccines 
and medications.  A recent influenza campaign at RCWMCH (Blake, 2013a) indicated the 
importance of communicating vital information both to the prescriber and caregiver of the 
child patient. Prescribers were informed in advance about the availability of the vaccine as 
well as the target population to receive the vaccines at RCWMCH, that is, the compromised 
and very sick child patients. Parents were also educated about the influenza vaccine and its 
benefit, ensuring the success of the influenza vaccination campaign. The memorandum on the 
influenza vaccination campaign was forwarded to the doctors and assisted in ensuring 
communication to all patients targeted; the result was that the target population was 
administered with the influenza vaccine in time, with minimal influenza cases reported.  
2.3 Prescribing error 
Pharmacology training focuses more on theory than on practice. The result of this is that 
many medical students remain unclear about how to prescribe a drug or what drug 
information to give their patients. The study material available to students is more likely than 
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not to be drug-centered, that is, concentrating on indications, side effects and so forth. In 
contrast, in clinical practice, a practical approach is required. Patients differ in age, gender, 
size, and socio-cultural characteristics, all of which may influence treatment choices. Since 
practical prescribing skills remain weak, prescribers may face more challenges when serving 
special population groups such as children (de Vries et al., 1994). 
Bad prescribing habits lead to ineffective and unsafe treatment, prolongation of illness, 
distress to the patient, and higher costs to the state and patient or their families or care givers. 
Bad prescribing habits also make the prescriber vulnerable to influences that can cause 
irrational prescribing, for example,  patient pressure and high-powered salesmanship by sales 
representatives of pharmaceutical companies. Yet, changing existing prescribing habits is 
very difficult. Good training, it is argued, is needed in the first place to prevent the 
development of poor habits (de Vries et al., 1994). 
There is no universal agreement as to what constitutes a prescribing error, with 
research studies varying in their definitions of the event. Often, studies include all medication 
errors and fail to distinguish clearly between prescribing and other types of errors (for 
example, administration errors, supply errors and so forth). For example, one study gives the 
general definition as a “mistake made at any stage in the provision of a pharmaceutical 
product to a patient” (Wilson et al., 1998). In the specific category of prescribing errors, the 
researchers included incorrect drug selection, incorrect dose or frequency, incorrect route, 
incomplete information (for example, a prescription not signed or a dose not stated), illegible 
prescription, unforeseen drug interactions, inadequate monitoring of drug levels and infusion 
error (Wilson, 1998). This particular study was conducted at the Congenital Heart Disease 
Centre at the University Hospital of Wales, with the hospital consisting of a 15-bed paediatric 
cardiac ward (PCW) and a four-bed cardiac Intensive Care Unit (ICU). Errors were 
documented by nurses, pharmacists, or doctors, using standardized incident report forms. 
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Individuals responsible for errors remained anonymous, creating a non-punitive environment 
and the Medication Error (ME) Committee, consisting of one senior doctor, one junior 
doctor, one nurse from each clinical area and a senior pharmacist, met at three-monthly 
intervals to analyze reports. The findings of the ME Committee were reported back to the unit 
staff in the form of written updates, along with recommended changes in practice. During the 
24-month study period, there were 682 admissions for a total of 5 315 inpatient days. A total 
of 441 error reports were submitted by nurses (61%), pharmacists (35%), and doctors (4%). 
Prescription errors accounted for 68% and included incomplete prescription (36%), incorrect 
dose (36%), incorrect frequency (11%), transcription error (7%), incorrect drug selection 
(4%), drug interaction (3%), and illegible prescription (3%). Interestingly, nurses, doctors, 
and pharmacists were all actively involved in reporting errors, be it supply, administration or 
prescription errors. 
Another study stated that a clinical meaningful prescribing error occurs when, as a 
result of a prescribing decision or prescription writing process, there is an unintentional 
significant (1) reduction in the probability of the treatment being timely and effective, or (2) 
increase in the risk of harm compared with generally accepted practice (Ghaleb et al., 2005). 
Interestingly, Ghaleb et al., (2005) used what is known as the two-stage Delphi technique 
over other methods to avoid direct communication between groups of experts while still 
allowing for a certain level of interaction between them. In this methodology, the views of a 
panel of expert participants about situations that should or should not be included as 
prescribing errors in paediatric practice was taken into consideration. Ghaleb et al., (2005) 
further mention that a practitioner-based definition of a prescribing error has been developed 
in the United Kingdom for use both in research and practice, but that the one limitation of this 
definition is its developed use for the adult setting with issues specific to paediatric practice 
such as the prescribing of drugs based on individual weight or age not considered. Ghaleb et 
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al. (2005) further state the objective of the study as being an intention to develop a 
practitioner-led definition of a prescribing error that could be applied to a paediatric setting, 
which could act as the foundation for future research into prescribing errors in paediatrics. It 
is with the similar aim in mind that current study was undertaken, that is, researching the 
prescribing practices at a paediatric hospital in South Africa to highlight the trend and 
associated risk factors, for example, age of the patient, level of experience of doctor and class 
of drug(s). 
According to the Delphi technique used in the study by Ghaleb et al. (2005), the 
definition of the prescribing error was raised in the form of a question, that is, what 
constitutes an error? Different scenarios of what represents a prescribing error were 
forwarded to the different participant’s, namely, the doctors, nurses, pharmacists, and other 
healthcare members. In the first stage of the Delphi technique, participants had to indicate 
their extent of agreement with the proposed definition of a prescribing error. In the second 
stage, participants restored agreement or disagreement for prescribing error scenarios where 
consensus was not reached in the first round. In this round, consensus was reached and thus 
there was no need to conduct a third round. The following definitions were specified before 
data was analyzed, namely, “consensus”, “agreement”, and “disagreement”. Where consensus 
existed, it was agreed that the scenario would be included as a prescribing error if the median 
score fell within the 7–9 range, excluded if it fell within the 1–3 range, and regarded as 
equivocal if it fell within the 4–6 range. Ethical approval was obtained from the Thames 
Valley multicenter ethics committee (Ghaleb et al., 2005). 
After consensus was reached, the authorities in the research study decided to retain 
the initial proposed definition of a prescribing error, that is, “a clinically meaningful 
prescribing error occurs when as a result of a prescribing decision or prescription writing 
process, there is an unintentional significant reduction in the probability of treatment being 
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timely and effective or increase the risk of harm when compared with generally accepted 
practice” (Ghaleb et al., 2005). 
Interestingly, of this definition could be applied to any paediatric setting, including a 
hospital such as the RCWMCH. The guidelines offered in the study Ghaleb et al. (2005) also 
pertain to the scenarios for inclusion and exclusion with regard to prescribing errors and can 
be useful in the local RCWMCH context as well. However, the drawbacks of the 
methodology used in the above study are of equal concern, especially considering the needs 
surrounding a prospective descriptive study in a teaching hospital like the RCWMCH. Firstly, 
involving different participants from different specialties would appear to be an impractical 
task; secondly, as with the Delphi technique, response rates would likely be less than 100% 
and the results therefore probably biased, that is, missing responses of participants would 
need to be considered. On the other hand, the high response rate would conclude the validity 
of the study. Nonetheless, the current advantage of the study by Ghaleb et al. (2005) is that 
globally there exists no standard definition of prescribing error, hence the definition and the 
scenarios can possibly be used internationally as a “rough” guide regarding what constitutes a 
prescribing error, thus allowing its use in research studies, such as the current one undertaken 
at a paediatric hospital like the RCWMCH. 
In an interesting retrospective cohort study carried out at the emergency department 
(ED) of the Hospital for Sick Children in Toronto Canada in 2000 , it was found that trainees 
are more likely to commit prescribing errors and, not surprisingly, seriously ill children are 
more likely to be subjected to prescribing errors (Kozer et al., 2002). In this study, the charts 
of 1 532 children treated in the ED of the paediatric tertiary care hospital were reviewed 
during 12 randomly selected days. The objectives of the study were to estimate incidence and 
type of errors and identify the possible factors (variables) likely to increase the risk of 
prescribing errors. Approval from the hospital ethics committee was obtained for the study 
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and two medical students served as research assistants. The data was extracted (under the 
supervision of one of the investigators) and incorporated into a database, which included 
information about patient demographics, clinical condition, diagnosis, acuity of the condition 
(based on the triage category), the prescribing physician and all the medication prescribed 
and administered to the patient. Drug doses differing from the recommended dose, deviation 
by two hours or more from the recommended interval between doses, wrong units and route 
of administration from the recommended regimen were all flagged as potential errors. 
Medication prescribed and not given, that is, omissions, and medication given without a 
properly written prescription, that is, prescriptions not legally compliant, were also flagged as 
errors. Medication errors due to prescribing errors were classified as: (a) 
insignificant/minimal risk, for example, a child receiving 5mg dexamethasone instead of 
3mg, (b) significant, for example, a drug error that could cause non-life threatening 
consequences or an error that would result in a less effective treatment for child’s condition 
(for example, a tenfold lower dose of amoxicillin for otitis media(OM)), or (c)  severe, that is, 
if a medication error could cause death or decrease the chance of successful treatment of a 
life threatening condition, for example, a tenfold error in insulin dosage or significant under-
dosing of antibiotics for a patient with meningitis. Potential errors in medications prescribed 
and administered at the ED or for home use were identified using 403 charts. A senior 
investigator reviewed a random sample of 50 charts and identified one additional error (not 
picked up by the research assistants). In 330 cases (81.8%), there was initial agreement 
between the reviewers regarding whether an error had occurred and the ranking of the error. 
In 49 of the remaining 73 cases, agreement was achieved between the reviewers after each 
case was discussed on an individual by individual basis. Twenty four cases were reviewed by 
a third researcher. Prescribing errors were identified in 154 charts (10%).The most common 
types of errors were wrong dose (49.1%), wrong frequency (43.2%), wrong route (2.6%), 
 
 
 
 
18 
 
wrong drug (1.8%), inadequate information (2.6%) and other (0.7%). The drugs most 
commonly involved in errors were acetaminophen followed by antibiotics, asthma 
medications, and antihistamines. Moreover, these were also found to be the most commonly 
prescribed drugs in the ED.  
The incidence of medication errors was calculated and logistic regression used to 
assess the likelihood of medication errors among patients for whom a medication was 
prescribed. The independent relationship between each variable and the outcome variable 
(error versus no error) was examined. Variables found to be significantly linked with drug 
errors or those that might confound the relationship between other variables and drug errors 
were included in a multivariate analysis. Multivariable logistic regression was used to 
identify factors such as age, gender, level of training of the physician, shifts, patients waiting 
time and triage category that independently influenced the rates of medication/prescribing 
errors (Kozer et al., 2002). 
Factors associated with an increased risk of medication errors included medication 
prescribed by a trainee as opposed to a staff physician and seriously ill patients being the 
most affected as compared with least ill patients. 
In another study conducted by Lesar et al. (1997) in a 631 bed tertiary teaching 
hospital in New York from July 1 1994 to June 30 1995, potential prescribing errors were 
defined as medication orders for the wrong drug, inappropriate dose, frequency, route, dosage 
form, inappropriate indication, ordering of unnecessary duplicate/redundant therapy, 
contraindicated therapy, medications to which the patient was allergic, prescriptions for the 
wrong patient, or missing information required for the dispensing and administration of the 
drug. All prescriptions were handwritten and copies of the originals sent to the pharmacy. All 
the prescriptions were reviewed by centralized staff pharmacists and entered into a pharmacy 
 
 
 
 
19 
 
computer system prior to dispensing. The pharmacy computer system had automated 
programs for dose-checking, duplicate therapy checking, allergy-checking and drug 
interaction checking capabilities. All prescriptions jointly determined by the physician and 
pharmacists to be in error, and subsequently changed, were considered “confirmed 
prescription errors”. A total of 905 prescribing errors were detected and confirmed during the 
1 year study period, with 522 (57.7%) of the errors detected rated as significant, that is, 
potentially fatal, potentially serious and potentially significant, classified A, B, and C 
respectively. A total of 289 411 prescriptions were written during the study period, with a 
daily average of 793 prescriptions. The overall prescribing error rate was 3.13 per 1 000 
prescriptions (0.31%) and there were 1.80 significant prescribing errors per 1 000 
prescriptions (0.18%). The overall frequency of medication prescribing errors was 0.44 per 
100 patient days (0.44%) and 0.25 significant errors per 100 patient days (0.25%). 
Medication prescription errors most frequently involved antimicrobials, which 
accounted for (23.1%) of all errors and 28.5% of all significant errors. Overdose was the most 
frequent type of error, occurring in 28.7% cases and accounting for 38.9% of significant 
errors. Prescribing errors involving missing information accounted for 22.3% errors but did 
not contribute to significant errors because of the low potential of such prescriptions being 
carried out. The most common medications involved in the 696 prescribing errors were 
antimicrobials, cardiovascular drugs (122 or 17.5 %), gastrointestinal agents (51 or  7.3%) 
and non-narcotic analgesics and antipyretics (46 errors or 6.6%). Error rates varied 
significantly among medication groups (P<0.001). Of the 696 errors, 43 (6.2%) were rated as 
A (potentially fatal or severe), 96 (13.8%) were rated as B (potentially serious errors), and 
557 (80 %) were rated as C (potentially clinically significant). The error rates were as 
follows: for surgical patients, 3.51 per 1 000 prescriptions, for medical patients, 4.12 per 1 
000 prescriptions for obstetric-gynecologic patients, 4.51 per 1 000 prescriptions, for 
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paediatric patients, 5.89 per 1 000 prescriptions and for emergency patients, 5.05 per 1 000 
prescriptions (p< .001, the difference among all groups). Interestingly, the most common 
specific factor related to prescribing errors was the presence of pathophysiological status or 
disease (such as cardiac failure, renal impairment, or hepatic failure) that required alteration 
of drug therapy (Lesar et al., 1997). 
A study such as the one above highlights the importance of knowledge of the drug, 
patient factors related to drug therapy, namely, age, disease state, for example renal 
impairment, and knowledge about the correct use of the drug. Although the Lesar et al. 
(1997) study focused mainly on the adult population, children were not excluded, as was 
noted in the error rates above. Thus, irrespective of the age of the patient, this study revealed 
that prescribing errors are a concern for children as well. The definition of prescribing errors 
used in the above study almost fits the one used in the current study conducted at the 
RCWMCH, but differs in that the Lesar et al. (1997) study included administration errors, 
whereas the study conducted at the RCWMCH did not include errors in the administration 
stage of medication management as a prescribing error. Furthermore, the study carried out by 
Lesar et al. (1997) involved a group of investigators and had the advantage of using an 
automated computer system to detect errors, which the current study did not. 
To illustrate the clinical significance of tenfold medication dose prescribing errors, 
from 1 July 2000 to 4 January 2002, in another study Lesar et al. (2002) identified and 
quantified the characteristics of such errors in a 631 bed tertiary care teaching hospital in 
New York (the same hospital used in the previous study conducted by Lesar et al. (1997)) 
between June 1994 and July 1995. This time around, the study also included the paediatric 
population, the said population group occupying 120 beds, including a neonatal intensive care 
unit (NICU) and paediatric ICU (PICU) as well as general paediatric beds. For all paediatric 
patients weighing less than 50kg, hospital policy required inclusion of the weight (gestational 
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age required for neonatal intensive care unit (NICU) patients), the equation used to calculate 
the drug dose and a final calculated dose amount. Medication prescribing error data for the 
study analysis were concurrently and systematically collected over an 18-month period as 
part of an ongoing error prevention/quality improvement program. As with the earlier study 
by Lesar et al. (1997) in the very same hospital, pharmacists routinely made use of all 
available information to evaluate the prescription for appropriateness, with  a prescription in 
question discussed between the pharmacist and the prescriber, then changed or discontinued 
and considered a potential prescription error. In the 2002 study, potential tenfold prescribing 
error was defined as medication prescriptions with a drug dose prescribed that was 10, 100 or 
1 000 fold greater or lesser than the correct dose for the patient. The mechanism for each 
error was determined as either adding a zero or omitting a zero or misplaced decimal point, 
the latter practice of which was found to be a common problem that appears to be frequently 
associated with medications with the dose <1 (for example, 0.05mg intended, prescribed as 
0.5mg) or doses containing multiple zeroes (for example, 3 000 units intended, prescribed as 
30 000 units). Failure to place a leading zero before a decimal point (for example, 1mg) 
include a zero following a decimal point (for example, 1.0mg) or use trailing zeroes (for 
example, 0.150) are a common cause in tenfold errors, especially in the interpretation of 
written prescriptions. This study also showed that the potential for patient harm resulting 
from errors in prescribing are greater than that for errors in preparation, dispensing or 
administration. It is important to note that in paediatric patients doses of the same drug vary 
so widely between patients that errors are not easily recognized. Of the 200 confirmed 
significant medication tenfold prescribing errors detected between 1 July 2000 and 4 January 
2002 in the Lesar et al.(2002) study, 161 (80.5%) occurred among adults and 39 (19.5%) 
among paediatric/neonatal patients. The tenfold errors accounted for 5.33% (200 of a total of 
3 758 detected prescribing errors) of all clinically significant prescribing errors detected by 
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pharmacists during the study period. During the 18 months in which the study was conducted, 
tenfold prescribing errors were detected at a rate of 0.53 errors per 100 total admissions and 
0.98 per 1 000 total patient days compared with a rate of 0.52 per 100 total admissions and 
0.77 per 1 000 patient days among adults. Overdoses occurred in 122 cases and under doses 
in 78 cases. The detected errors were rated as potentially severe or serious in 90 (45%) of 
cases. The mechanism for the tenfold error in prescribing was pinpointed to a misplaced 
decimal point in 87 cases, the addition of an extra zero in 63 cases, and the omission of a zero 
in 50 cases. 
In a study that focused on antimicrobial prescribing errors for children in 
Christchurch, New Zealand, the appropriateness of antimicrobial treatment of children 
admitted to a paediatric unit was assessed (Grimwood, Cook & Abbott, 1983). During the 
audit period, 255 children were studied; their ages ranged from five days to 12 years and they 
made up 52% of 487 children admitted to hospital for treatment of infection. All prescriptions 
were written by junior doctors, and after reviewing the recorded information, that is, drug, 
dose, frequency, route and duration, the auditors made a collaborative assessment about the 
appropriateness of the therapy. When the auditors differed, consensus was reached via 
favoring a practical over an ideal therapeutic approach. Prescribing errors for each 
antimicrobial were classified into the following categories: (1) antimicrobial not indicated; 
(2) incorrect choice; (3) incorrect dosage; (4) incorrect frequency; (5) incorrect route; and (6) 
incorrect duration. Of the 203 antimicrobials dispensed, 130 (64%) were found to have been 
used appropriately. Errors tended to occur most frequently in the area of dosage, with 55 
(27%) of prescriptions incorrect in this regard. There was a tendency to chart dosages too low 
for the diseases for which they were prescribed, with this practice observed most commonly 
for oral agents. Prescribing of aminoglycosides in 20 patients was considered inappropriate in 
11 (55%), the major error being failure to adequately monitor serum levels and alter the 
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dosage or frequency accordingly. Chloramphenicol was used to treat 10 patients, with its use 
considered inappropriate in four (40%). Errors included a wrong dose and prolonged 
ampicillin/chloramphenicol combination treatments in three children with bacterial 
meningitis. This combination was used for three or four days despite there being 
microbiological data indicating the nature and sensitivity of the infecting organism 12 to 24 
hours after commencement of treatment. Incorrect choice of drugs was infrequent (7%) and 
related mainly to using broad-spectrum agents such as amoxicillin where penicillin would 
have been more appropriate (Grimwood, Cook & Abbott, 1983). 
The above study, conducted 31 years ago, indicated the increased prevalence of 
resistant bacteria to be the direct result of antimicrobial misuse. Unfortunately, this practice is 
still observed in most hospital settings globally and is unlikely to change any time soon as 
newer antibiotics, considered more sophisticated, continue to be released into the market. 
Antimicrobial resistance, once very uncommon in children, has increased in this age group, 
posing a challenge for infectious disease physicians, especially in patients with co-morbid 
diseases. However, prescribing errors can be reduced if physicians adhere to proper 
prescribing guidelines and consult with the expertise in the field of infectious disease, failing 
which the war against micro-organisms will fail. 
To date, most medication error studies have been carried out for adults. However, 
potential adverse drug events (ADE’s) (this term includes adverse drug reactions (ADR’s) 
and medication errors (ME)) may be up to three times more common in children than in 
adults (Kaushal et al., 2001). Most potential reported ADE’s show dosing errors and errors 
involving IV administration. The Department of Health in the United Kingdom has 
recognized that children constitute a particular challenge as regards the safe use of medicines. 
Recently published literature reviews have established medication errors as a significant 
problem in paediatric practice there (Ghaleb & Wong, 2006; Walsh, Kaushal & Chessare, 
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2005). In one such systematic review (Wong et.al., 2004), researchers found the true 
incidence of paediatric dosing errors to be approximately 500 000 per year in England. Based 
on these findings and the fact that ADRs and MEs are under-reported or hardly ever reported 
in South African hospitals, there is thus an urgent need to minimize any further such potential 
errors. Although hospital formularies and standard treatment guidelines (STGs) are readily 
available for prescribers to use, it is still not common to comfortably locate prescriptions 
within the fold of good prescribing protocols. The American Academy of Paediatrics (AAP) 
has also recognized the importance of identifying and managing MEs in children. The Drug 
and Therapeutics Committee of the Hospital Care section of the AAP emphasizes the 
importance of systems change in detecting and preventing MEs among inpatients. It 
enumerates substantial recommendations covering not only prescribers, pharmacists, and 
nurses, but also the hospital system and parents (Koren, Barzilay and Greenwald 1986). 
It was of paramount importance that a definition of paediatric prescribing errors be 
established before conducting a study at a paediatric hospital such as the current one at 
RCWMCH. The definition of a prescribing error is vital to the  study, seeing as such a 
definition can significantly influence the number of errors identified. For the study at 
RCWMCH prescriptions complying with the defining terms constituting a correct 
prescription, that is, prescriptions in accordance with the Medicines and Related Substance 
Act 101 of 1965 (Medicines and Related Substance Act 101 of 1965, Regulations as 
amended,2014: 28) were regarded as correct for the purpose of this study.The act requires the 
following information with regard to the prescriber, patient, and drug: (a) name, qualification 
and practice number, and address of the prescriber, (b) name, address, age, and sex of the 
patient, and (c) approved name of the drug, dosage form, strength of dosage form, and 
quantity of medicine to be supplied. In the case of Schedule 6 drugs, the quantity is to be 
written in figures and words, with instructions for the administration of the dosage, frequency 
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of administration, and the duration clearly stipulated on the prescription. In addition, the date 
of the prescription must be clearly recorded, with the whole prescription needing to be in 
legible hand written or typed print.  
 
2.4 Drug-drug interactions  
Prescribers often prescribe a number of drugs belonging to different classes, each with their 
own side effect profile. Drug-drug interactions (DDIs) are often overlooked. This oversight 
can and does interfere with the outcome of drug treatment, that is, causing therapeutic failure 
and drug toxicity. It is true that not all DDIs are bad, that is, some drug interactions are seen 
as synergistic or even beneficial to the patient. Prescribers, however, must take into 
consideration the potential for harm that drugs may have when they are administered in 
combination as part of a therapeutic drug regimen. Antiretroviral (ARV) drugs are not to be 
ignored when it comes to DDIs. The treatment of HIV-infected patients is a challenge for 
many a healthcare professional, made more complex in the case of HIV-infected children. 
Drug interactions involving metabolism are the most difficult to predict and constitute the 
most common problems for prescription errors. Some drugs may interact in more than one 
way, acting as an inhibitor and inducer of different CYP450 enzymes. The prescriber dealing 
with HIV-infected children has to prescribe responsibly to ensure that prescribed medication 
has more benefit than risk to the patient. It is predictable that drug interactions occur in 
almost all patients being treated for HIV/AIDS, due largely to the average number of drugs 
prescribed for treating the virus and the opportunistic infections it causes (Katenda-Kyenda et 
al., 2011). 
ARV’s have transformed HIV/AIDS into a chronic disorder that can be managed 
effectively, with the right of all HIV-infected adults and children to receive standard care 
endorsed by the SA HIV Clinicians Society (SAHIVCS). ART guidelines recommending 
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different treatment combinations are also provided for. With the increased number of 
approved ARVs, the risk of prescribing errors increases, as well as the dispensing of incorrect 
dosages and/or dose frequencies and incorrect reporting of drugs by the patient to the 
prescriber, all of which lead to treatment failure. DDIs are an under recognized consequence 
of medication prescription errors, resulting in significant healthcare costs. DDIs determine 
both positive and negative consequences of treatment for HIV- infected patients and 
SAHIVCS and the NDoH in South Africa have made recommendations with regard to a 
number of drug combinations and adjustment of dosages concerning certain co-administered 
drugs (Katende-Kyenda et al., 2011). 
In a non-experimental retrospective quantitative study Katende-Kyenda et al. (2011) 
described the prevalence of ARV prescriptions with potential DDIs and evaluated their 
prescribed daily dosages (PDDs) with specific reference to the prescriber and age group. The 
study was performed over a 24-month period on data received from a South African 
Pharmacy Benefit Management (PBM) company. Confidentiality was strictly maintained to 
ensure non-identification of patients, medical practices, pharmacies, or medical schemes 
involved. Permission to conduct the study was granted by PBM and ethics approval was 
obtained from the research and ethics committees of the North West University and the 
Walter Sisulu University. Potential DDIs between ARVs were identified and classified as 
clinically major, moderate, or minor. The study was performed using 49 995, 81 096, and 88 
988 ARV prescriptions made for 7 664, 10 162, and 10 061 HIV patients in 2005, 2006, and 
2007, respectively. ARV prescriptions represented 0.59% (N = 49 995), 0.90% (N = 81 096), 
and 1.11% (N = 88 988) of the medical aid claims for the three years. ARV prescriptions 
from general practitioners (GPs) with potential DDIs and incorrect PDDs increased from 
12.33% in 2005 to 24.26% in 2007. Prescriptions from specialist practitioners (SPs) increased 
from 15.46% in 2005 to 35.30% in 2006 and decreased to 33.16% in 2007. The highest 
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numbers of incorrect PDDs with DDIs were identified in ARV combinations as follows: 
lopinavir-ritonavir 1066.4mg/264mg with efavirenz 600mg , and lopinavir/ritonavir 1 
066.4mg/264mg with nevirapine 400mg, followed by indinavir 1 600mg with ritonavir 
800mg, ritonavir 600mg with efavirenz 600mg and saqinavir 800mg with efavirenz 800mg 
for both GPs and SPs. Although combination ARV therapy is potent and effective for HIV 
infection, ARVs frequently interact among themselves as many are metabolized through the 
same CYP450 system.  
A study such as the one above clearly illustrates the importance of appropriately 
prescribed ARVs for adult and children, more so in children who are not sufficiently 
pharmacokinetically developed to buffer serious adverse effects due to DDIs. The outcomes 
of interactions are not always easy to measure in the absence of a concerted effort by 
healthcare professionals to keep records of unexpected adverse drug events. As stated earlier, 
while it should be noted that not all drug interactions are harmful, with some drug 
interactions possibly beneficial with potential synergistic use to produce a desired outcome, 
the concern should be on those that are not. 
As previously mentioned, paediatric patients react to drugs differently than do adults. 
In particular, extended half-life of metabolised drug and reduced excretion may result in 
toxicity problems. A descriptive study of drug interactions in hospitalised children 
undertaken by Martinbiancho et al. (2007) and others from January 2005 to December 2006 
in a teaching hospital in Brazil helped to verify rates of drug interactions and their clinical 
meaning in prescriptions for paediatric patients during the period of hospitalisation. The 
study included patients aged 0–12 years with four or more drugs in their prescriptions, 
excluding topical drugs. The study excluded patients hospitalised in emergency areas, ICUs, 
and the oncology unit. Patients’ electronic prescriptions were analysed three times a week by 
a pharmacist and two scholarship holders in pharmaceutics. The Micromedex/Drug Reax 
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program was used to analyse drug interactions and incompatibilities. Based on the 
interactions found, an analysis was performed on their relevance to the patients’ respective 
conditions and the medical team informed of the findings. The drug interactions were 
classified in terms of interaction severity, effect start, and literature documentation. For the 
duration of the study period, 3 170 patients were investigated, with 11 181 prescriptions 
analysed, producing a mean of 3.5 prescriptions per patient. The mean quantity of items per 
prescription was 10. These prescriptions contained 6 857 drug interactions, that is, 1.9 
interactions per prescription and seven interactions per patient. The most frequent drug 
interactions were ampicillin and gentamycin in 220 (3.2%) prescriptions, diazepam and 
chloral hydrate in 215 (3.1%), and valproic acid and phenobarbitone in 214 (3.1%) 
prescriptions. In total, 1 201 (5.6%) drug interactions were brought to the notice of medical 
teams, with 204 (17%) of severe level, 672 (56%) of moderate level, and 325 (27%) of mild 
level. 
The above study showed that although the number of clinically relevant drug 
interactions was considered low, many hospital admissions were linked to effects caused by 
the interactions of utilised drugs. The computerised system used to identify and verify 
potential drug interactions is an excellent means of helping health professionals prevent 
severe drug interactions. In a dynamic working environment and specialised teaching hospital 
such as the RCWMCH, the Micromedex/Drug Reax system, if adopted, could prove of great 
benefit in the future. Interestingly, the drugs identified in the study to be most frequently 
involved in drug interactions are drugs also commonly used at the RCWMCH, for example, 
the concurrent prescribing of valproic acid and phenobarbitone, ampicillin and gentamycin, 
and chloral hydrate and diazepam. 
In a study carried out by Goldberg et al. (1994), an analysis of high risk population 
involved in potential drug-drug interaction was considered. This study only included subjects 
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50 years and older. Yet, based on the findings by these researchers, one cannot discount the 
possibility that perhaps children, if they had been included, may have shown similar 
outcomes since most of the drugs involved in the study are drugs also commonly used in the 
paediatric population. The retrospective study by Goldberg et al. (1994) was carried out the 
EDs of two facilities, namely, a community hospital ED (referred to in the study as facility 1 
and a general teaching hospital ED (facility 2). The general hospital has a volume of 
approximately 160 000 ED visits per year and the community hospital that of 30 000. Three 
24-hour periods were randomly selected at each facility during the months of January and 
February 1994. All patients receiving three or more medications and any patient 50 years of 
age or older taking at least two medications were included in the study. Data collected 
included: age, gender, reason for admission, medications taken prior to ED visit, medications 
administered in or prescribed at the ED, and discharge diagnosis. Potential drug interactions 
were analysed using the Drug Master Plus computer software program, with the editors 
defining a moderately significant interaction as one in which the potential for interaction is 
increased and possible harm to the patient with prolonged use of the drug combination. A 
total of 205 patients were studied, 111 from facility 1 and 94 from facility 2; the study groups 
were similar with respect to mean age and number of patients with hypertension, diabetes, 
renal failure, and congestive heart failure.  
Overall, 89 of 191 patients (47%) had a total of 226 potential adverse drug 
interactions (ADI’s), 50% of which were related to ED treatment. No significant differences 
between the facilities were found. The potential for ADIs increased with the number of 
medications administered, with 13% of patients taking two medications at risk for ADI as 
compared to 38% taking five medications and 82% taking seven or more medications. Of a 
total of 226 potential drug interactions, 11 drugs accounted for 223 (98%). An analysis of 
these drugs in terms of relative risk of drug interaction between patients administered versus 
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those not administered commonly interactive drugs showed that digoxin and furosemide had 
significant p values (p<0.0001),nifedipine (p<0.0098), enalapril (p<0.0070), ranitidine 
(p<0.0015), and glyburide (p<0.0423). P values with respect to relative risk failed to reach 
significance for prednisone, prochlorperazine, dilantin, and aspirin. 
That these studies were carried out only in the EDs of the hospitals does not mean that 
similar results could not have been obtained in the general wards of the same hospitals, since 
all the drugs indicated above are commonly used throughout the hospitals. Children also form 
part of the patient pool that visit the EDs of hospitals, thus a significant population group was 
excluded in the study, that is, the relative risk of potential drug interaction could have shown 
more interesting results if they had been included. 
In a study performed in two cities in Pakistan, namely, Faisalabad and Sargodha, in 
2009 by Sajid et al. (2011) a comparative assessment of drug interactions in children at 
private and public sector hospitals illustrated the importance of including the paediatric 
population when researching drug interactions. Interestingly, the researchers considered drug 
interactions as a type of prescribing error. 
The medication records of hospitalised paediatric patients from May to August 2009 
were screened for drug interactions. The study included hospitalised children aged 12 years 
and below with three or more drugs in their prescriptions. Topical drugs were excluded, as 
were children hospitalised in emergency and intensive care units. A computerised software 
program developed by Medical Letter 2002 was used to analyse potential drug interactions 
classified as severe, moderate, or mild. Comparative data of a total 1 420 prescriptions were 
collected, with a total of 950 drug interactions found, that is, 66.90%. Among the total drug 
interactions found, the public sector hospital showed 820 out of a total of 1 100 prescriptions, 
that is, 74.55%.  In the private sector hospitals in both cities, the total number of drug 
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interactions found was 130 out of 320 prescriptions, that is, 40.63%. The total number of 
paediatric patient admissions in the public sector hospital in Faisalabad was 2 681 from May 
2009 to August 2009, with 680 prescriptions selected. The number of drug interactions found 
was 430 out of the 680 prescriptions, that is, 63.24%. The data of 420 from 1 680 admissions 
from the sole public sector hospital in the city of Sargodha were also collected. The total 
number of drug interactions found was 92.86%, with 390 out of 420 prescriptions. Regarding 
the types of drug interactions, 19 types were found in the public sector hospital studied in 
Faisalabad, 24 (3.5%) of these being severe, 242 (35.6%) moderate, and 164 (24.1%) mild. 
Examples included interactions between ampicillin and cefotaxime (16.2%) and isoniazid and 
rifampicin (2.3%). In the public sector hospital in Sargodha, 20 types of interactions were 
observed, with 3.8% being severe, 73.3% moderate, and 15.7% mild. 
 In the private sector hospital, from May to August 2009, a total of 320 prescriptions 
were analysed, with 200 from two hospitals in Faisalabad and 120 from two hospitals in 
Sargodha. The total number of drug interactions found in the private sector of Faisalabad 
were 40 out of 200 prescriptions (20%), with  six types, 18 of which (9.0%) was mild and 22 
(11%) moderate; no severe drug interactions were found. A total of 90 (75%) drug 
interactions of nine different types were found in the private sector hospitals in Sargodha, 
with 19 (15.8%) being mild, 65 (54%) moderate, and 6 (5.0%) severe. These findings show 
that the public sector hospitals of both cities experienced a greater percentage of drug 
interactions compared to the private sector hospitals. The public hospitals of Faisalabad 
showed a better performance (63.24%) where specialised prescribers were available, 
compared to the public sector hospital of Sargodha, in which the whole city had only two to 
three specialist paediatricians. On the other hand, both public sector hospitals had 
pharmacists, but these were involved in purchasing of medicines and not in clinical activities. 
The private sector hospital of Faisalabad showed only 25% of drug interactions as compared 
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to the private sector hospital in Sargodha, which had 75% of drug interactions. This could be 
attributed to the Faisalabad hospital having more pharmacists than did the private sector 
hospital in Sargodha. 
The above study clearly demonstrates the potential for drug interactions in the 
paediatric population, irrespective of the type of healthcare setting, that is, private or public. 
It also highlights the importance of specialists involved in the role of prescriber rather than 
junior doctors as well as the presence of clinical pharmacist on the ward rounds. 
 
2.5 Drug-disease interactions  
A drug-disease interaction (DDiS) occurs when a medicine worsens a pre-existing disease 
(Lindblad et al., 2005). This is a concern, especially for elderly patients who may have more 
than one chronic condition and also for the paediatric population, who have immature organ 
function, thus placing them more at risk for DDiS. 
Choosing the correct drug and correct dose can thus be a challenge in the face of a 
chronic disease. Interestingly, the most profound interactions will occur when the disease 
process affects organs involved in drug disposition. Important examples of drug-disease 
interactions are described in the list that follows:  (a) Cirhossis and other liver diseases can 
impair the ability of the liver to metabolise drugs. Drug toxicity may result if hepatic 
impairment is not considered, with therapeutic drug monitoring being important in patients 
with pre-existing liver diseases. (b) In patients with renal disease, prostaglandins  assists in 
maintaining residual renal function. If drugs, such as non-steroidal anti-inflammatory drugs, 
are used in compromised patients, inhibition of cyclo-oxygenase will take place, resulting in 
a decline in residual renal function and consequently impaired renal excretion may occur (c) 
Viral infection suppresses hepatic cytochrome P450, perhaps as a result of interferon 
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induction. A patient with a plasma drug concentration at the upper end of the therapeutic 
range could therefore suddenly show signs of drug toxicity during a viral infection. (d) 
Achlorhydria (lack of stomach acid) may affect the site of absorption of drug formulations 
with a pH dependant coating. (e) The choice of a diuretic for a patient with cardiovascular 
disease is influenced by whether the patient has osteoporosis. Hydrochlorthiazide is a diuretic 
that does not increase renal elimination of calcium, which makes it the diuretic of choice in 
this type of patient. (f) Anticholinergics can increase cognitive impairment in patients with 
Alzheimer-type dementia (Page et al., 2002). Children, especially the very young, are 
disadvantaged when one considers their immature organ systems vis a vis the drugs that 
needs to be administered, metabolised, and excreted by the liver and kidneys, especially in 
the case of a chronic condition, such as chronic liver disease or end stage renal disease, add to 
the malfunction of their very same immature organs. 
To illustrate the interactions of age, genetics, and disease severity on tacrolimus (an 
immune-suppressive drug) dosing requirements after paediatric kidney and liver 
transplantation, de Wildt et al. (2011), conducted a retrospective study in paediatric liver and 
kidney transplant patients who received tacrolimus in the first 14 days after transplant. 
Children, aged between 0–18 years eligible for study purposes had at the time of liver or 
kidney transplant received tacrolimus during the first 14 days post-transplant. The study was 
conducted on such patients between 2000 and 2008 at the Hospital for Sick Children in 
Toronto, Canada. All patients who received tacrolimus in the first two weeks after transplant 
were approached for informed consent when they visited the out-patient clinic between 
November 2006 and February 2008. All the patients received the transplant immune-
suppression protocol therapy, namely, methylprednisolone, mycophenalate mofetil, and 
tacrolimus. The tacrolimus starting dose was 0.1mg/kg orally twice daily for all patients, 
adjusted by routine pre-dose tacrolimus concentrations to reach the preset target tacrolimus 
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concentration of 10–15ng/ml. Doses were adapted by the transplant physician in 
collaboration with the pharmacist. Tacrolimus doses (date/time) and morning pre-dose blood 
concentrations (date/time) were collected. The primary outcome measure was median 
tacrolimus dosing requirement and secondary outcome measures were median tacrolimus 
concentrations and concentration/dose ratio. The independent variables included recipient 
age, CYP3A5 and ABCB1 genotype, and PRISM (paediatric risk of mortality) score, a 
measuring score widely used in paediatric intensive care setting assessing the severity of 
illness and the potential risk of mortality in critically ill children. The total transplant cohort 
at the transplant unit as of February 2008 was 124 kidney and 91 liver transplant patients, 
with approximately 80% having received tacrolimus in the first two weeks of transplant. 
Overall, 42 paediatric liver recipients and 48 kidney recipients were enrolled in the study. 
The liver recipients were much younger than the kidney recipients, with the median range as 
follows: 1.5 years (range: 0.05–14.8) and 11.5 years (range: 1.5–17.7), respectively. Median 
durations of mechanical ventilation and stay at the ICU were longer in the liver patients than 
in the kidney patients. Children aged younger than 5 years needed higher tacrolimus doses 
per kilogram of bodyweight than did older children for both kidney and liver transplants. For 
kidney transplant patients, the median was 0.15 (range: 0.07–0.35) versus 0.09 (0.02–0.20) 
mg/kg 12-hourly, p = 0.046. For liver transplant patients, the median was 0.12 (range: 0.04–
0.32) versus 0.09 (range: 0.01–0.18) mg/kg 12-hourly, p = 0.038). The PRISM mortality 
scores were not correlated with tacrolimus dosing requirements, tacrolimus trough 
concentrations, or concentration/dose ratios in both transplant groups. 
Although a study such as the one above did not find any relation between disease 
severity and drug disposition, DDiS cannot be overlooked, as the following study revealed. 
In a study carried out at two separate facilities, namely, a general teaching hospital 
and a community hospital in the United States in 1994, no significant difference was found 
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between the two facilities with regards to the analysis of DDiS and the relative risk of DDIs. 
This study was undertaken by Goldberg et al. (1994) to determine not only the potential for 
drug-disease interactions, but also for potential adverse drug interactions, as has been 
previously mentioned in section 2.4 above of this literature review. A sample of ED records 
from each hospital was reviewed for potential drug-disease interaction. Existing medical 
conditions and newly diagnosed medical conditions were entered into the computer software 
program and compared with a list of the patient’s medication. Clinical interaction was 
defined by the program editors based on the drug manufacturers’ current package labelling 
and data derived from standard medical references. Relative risks were derived for the 
incidence of drug-disease interactions between groups who had and did not have the disease. 
Overall, 44 of 205 patients (21.5%) had a total of 94 potential drug-disease interactions, of 
which 32 (34%) were related to ED treatment. Leading drug-disease interactions included: 
albuterol-hypertension (4.8%); furosemide-diabetes (3.9%); prednisone-hypertension (2.9%); 
ibuprofen-hypertension (1.9%); albuterol-diabetes (1.95%), and prednisone-diabetes (1.4%). 
Goldberg et al. (1994) found that patients in this study population appeared to have 
substantial risk for drug-disease interactions (22%). Furthermore, the study revealed that 
approximately a third of potential DDiS were attributable to medications administered or 
prescribed in the ED. The outcome for the relative risk of drug-disease interaction between 
patients versus those with commonly encountered diseases showed interesting results. For 
example, patients with congestive heart failure (CHF) had a higher incidence of drug-disease 
interactions (54%) compared to those without (19.4%); hypertension (42.4%) compared to 
those without (14.4%); diabetes (51.5%) compared to those without (18.4%), and renal 
(57.1%) compared to those without (20.9%). 
This study clearly illustrated that DDiS should be considered in all population groups, 
including children, the latter who despite their young age, may suffer from the same adult 
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disease(s) mentioned in the above study, with physicians prescribing similar medications for 
children as for adults. This is even more pertinent if one considers that it is not uncommon to 
see children with advanced HIV and tuberculosis (TB) as a co-morbid disease, especially in 
the developing world and at the RCWMCH where the current study was conducted. 
A study conducted by Sahai et al. (1997) illustrated the importance of considering the 
drugs and disease state of the patient at the time of prescribing. This study found that reduced 
total drug exposure to rifampicin and pyrazinamide was associated with d-xylose  
malabsorption in persons with HIV infection and that peak drug exposure to isoniazid was 
lower in patients with diarrhoea. A total of 48 TB-free persons took part in the study and 
included: 12 healthy participants who were HIV- uninfected (Group 1); 12 HIV sero-positive 
asymptomatic patients with a CD4 T-cell counts greater than 200 cells per cubic mm (Group 
2); 12 HIV seropositive patients with a CD4 T-cell counts less than 200 cells per cubic mm 
(Group 3); and 12 HIV seropositive patients with a CD4 T-cell count of less than 200 cells 
per cubic mm and persistent diarrhoea (Group 4). Exclusion criteria were age below 18 years, 
pregnancy, abnormal liver function tests, serum creatinine levels >200 micromole/L, 
haemoglobin levels <100g/L, active opportunistic disease, and known hypersensitivity to any 
of the medications involved in the study. Study participants received 300mg isoniazid, 600mg 
rifampicin, 1 000mg of pyrazinamide, and 1 000mg of ethambutol daily, administered at the 
same time over three consecutive mornings. Therapy with other medications was stopped at 
least 24 hours before the study commenced and for its duration (five days). In order to 
measure the absorptive function of the intestines, with participants receiving 25g of D-xylose 
with 400ml water 24 hours after administering of the final dose of the anti-TB drugs. In this 
study, concentrations of all the anti-TB drugs were measured with high-performance liquid 
chromatography; however, analytic difficulties precluded the measurement of ethambutol. A 
colorimetric method was used to measure D-xylose. A comparison was made between the 
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plasma drug concentrations and time. It included data such as highest observed drug 
concentrations (Cmax), the time to Cmax (tmax), the terminal disposition half-life, and the 
area under the plasma concentration time curve (AUC) over the 24 hour dosing interval. Fast 
acetylators were distinguished if they had an isoniazid half-life of less than 130 minutes. 
There were 4, 10, 6, and 7 fast acetylators in groups 1, 2, 3, and 4 respectively. Fast 
acetylators had a shorter half-life and lower AUC value than slow acetylators. The trend 
analysis indicated a significant linear decrease in mean AUC with group order for 
pyrazinamide (p = 0.0002) as well as a significant linear decrease in Cmax for rifampicin (p = 
0.0006), and isoniazid (p = 0.046). Consistent with the trend for decreasing AUC and Cmax 
values from groups 1 to 4, statistically significant decreases of 18% to 41% in these variables 
were seen for some of the group contrasts for each drug. This study revealed that total 
systemic drug exposure was reduced for rifampicin by 32% and for pyrazinamide by 24% in 
persons with HIV-infection compared with the healthy controls, probably reflecting 
decreased bio-availability. Isoniazid was generally well absorbed in HIV-infected patients 
compared with healthy controls, which may partially explain a lack of correlation with the D-
xylose AUC. The 39% decrease in peak exposure and 0.74-hour increase in time to peak 
exposure suggested that diarrhoea reduced the rate of isoniazid absorption in symptomatic 
patients. The significant correlation between the D-xylose AUC and rifampicin and 
pyrazinamide AUC implies an absorptive defect. However, gastrointestinal malfunction may 
also increase rifampicin clearance by reducing its reabsorption during enterohepatic 
circulation, which explains why rifampicin was associated with the largest decreases in total 
and peak exposure. 
A study such as the one above demonstrated that HIV-infected patients, especially 
those in the advanced stage of the disease, have lower plasma concentrations of one or more 
anti-TB drugs, particularly rifampicin, compared with healthy subjects. That HIV-infected 
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children were not included in this study does not exclude them from being considered at risk, 
considering the challenges posed when anti-TB drugs are administered to them as part of the 
similar treatment they receive as for adults. As mentioned previously, children are 
pharmacokinetically more challenged than are adults and parameters such as half-life, bio-
availability, and plasma under the concentration-time curve should be considered at the time 
of prescribing, especially when other co-morbid conditions, for example, diarrhoea and 
failure to thrive (FTT), are present. The situation can be a bit more complex when the 
prescriber is faced with the challenges of HIV-infected patients with multiple drug resistant 
(MDR) and extreme drug resistant (XDR) TB, where treatment regimens need to be revised. 
Right at the onset of making a prescribing decision, the prescriber must take into account the 
potential for drug-disease interaction when prescribing for a vulnerable group, such as HIV-
infected patients with TB. 
A study by Schaaf et al. (2009) in Cape Town between 2004 and 2006 illustrated that 
both HIV- infected and HIV-uninfected children with TB required higher doses of rifampicin.   
A total of 60 children (26 HIV-infected and 34 HIV-uninfected children) were enrolled for 
the study at the Brooklyn Hospital for Chest Diseases (BHCD), a referral hospital for TB in 
Cape Town. The study period spanned January 2004 to December 2006. Fixed dose 
combinations of rifampicin (RMP) 60mg, isoniazid (INH) 30mg, and pyrazinamide (PZA) 
150mg (rimcure) was used during the intensive phase, with rifampicin 60mg and isoniazid 
30mg used during the continuation phase of TB. Rifampicin plasma concentrations were 
measured within a week of admission to BHCD and again four months after commencement 
of treatment to evaluate the possible influence of nutrition, disease state, and intra-individual 
variation on RMP pharmacokinetics. In the course of the study, four children (all HIV-
infected) were transferred back to referral hospitals due to complications that could not be 
managed at the BHCD, and a further two discharged (one HIV-infected and HIV-uninfected). 
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The remaining children received a mean RMP dosage of 9.61mg/kg for the pharmacokinetic 
study on enrolment and 9.63mg/kg during the four-month study. The mean calculated 2-hour 
RMP concentrations of the HIV-infected and HIV-uninfected children on enrolment were 
3.90 and 4.78 mcg/ml, respectively, with the standard deviation (SD) of the HIV-infected 
group (3.25) significantly greater than that of the HIV-uninfected group, (1.67). At the first 
pharmacokinetic evaluation on enrolment, only five children (9%) had calculated two-hour 
concentrations >8mcg/ml, while 25 (47%) had values <4 mcg/ml, although more HIV-
infected than HIV-uninfected children had values as low as 57% and 41%, respectively. Four 
months after the start of treatment, three children (6%) had two-hour RMP concentrations >8 
mcg/ml and 25 (43%) values <4 mcg/ml, with 39% HIV-infected and 43% of HIV-uninfected 
children showing such low values. While the results of the above study may perhaps be of 
little or no consequence in the management of less serious forms of TB in children, it might 
well be relevant in more severe forms of the disease, such as those encountered in the 
developing world, especially in association with HIV infection (Schaaf et al., 2009). 
 
2.6 Off-label prescribing 
Medical practice in recent years changed in numerous ways as compared to the past. The 
natural healer or physician of the past prescribed custom-made prescriptions, based on the 
individual’s needs, with the pharmacist practising what is called secundum artum (according 
to the accepted practice of a profession, for example, pharmacy for dispensing) to an 
individual patient. Medical practice in the past, in essence, fashioned itself as per the custom 
made prescription. In contrast, medical practice presently is now shaped by a huge drug 
market, with the pharmaceutical industry as the supplier, the patient as the customer, and the 
physician as the prescriber, the latter, ideally prescribing drugs based on evidence and 
according to standard treatment guidelines (STGs). Along with the benefits that came with 
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new diagnostic procedures and drug supply as the practice of medicine grew, a number of 
dramatic setbacks may also be observed. For example, adverse physical effects of new drugs 
developed by the ever-expanding pharmaceutical industry on patients, such as, 
diethylstilbestrol induced cancer in some girls, Grey’s syndrome in new-borns caused by 
chloramphenicol, coagulation factor preparations infecting patients with HIV, not forgetting 
hundreds of babies born with malformations induced by thalidomide. As a result, 
governments continue to develop laws to oversee correct marketing, selling, and consumption 
of drugs, with pharmaceutical companies legally obliged to provide pre-clinical efficacy and 
safety data from testing on animals, as well as results of clinical trials on humans to prove 
safety profiles and efficacy for the intended indication of a new drug before it is released in to 
the market. Thus the label was born. When a drug is approved for market release, the 
indications and dosages form part of the package insert and it is for the particular situations 
indicated that the risk-benefit ratio would have been reviewed and accepted by the regulatory 
authorities. However, different dosages, modifications of the formulation, for example, 
crushing tablets to make “special formulations” for children, and different routes of 
application (such as parenteral solutions for oral administering) mean that drugs are used 
without the legal protection of their labels, that,  off-label (OL) use.  
If there is an argument for the need to control the drug market, gained from historical 
lessons learnt about the developing organs of children which place them at risk from 
systematic drug toxicities, why is it common practice for children to be subjected to off-label 
(OL) drug prescribing? (Boos, 2003). In fact, the few studies done on the subject reveal the 
various concerns relating to off-label prescribing and show that the younger the patient and 
the more critical and rare the illness, the more likely will be the need for treatment that is off-
label. 
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A study conducted in the English Midlands in 1997 by Conroy et al. (2000) showed 
that off-label prescribing is common practice. It would be wrong to assume or generalise that 
unlicensed or “off-label” medicines are either potentially harmful to children or that they do 
not cause any harm, since in many cases they prove to be of great therapeutic benefit. 
Nonetheless, in the absence of testing and licensing, we cannot know if this is the case, nor 
can we know if children have suffered actual harm from taking medicines prescribed OL. It is 
also surely wrong that clinicians treating children should be faced with a situation of having 
to guess the “appropriate” dose and route of a medicine for a child patient. It would thus be 
interesting to know the prescribing habits of physicians as far as unlicensed and off- label 
prescribing is concerned.  
In one such study, prescribing habits with regard to unlicensed and off- label 
medicines in neonatal ICU patients were assessed (Conroy, McIntyre &Choonara, 1999). 
This was a prospective study conducted over a 13-week period in1998 in the United 
Kingdom and the clinical research pharmacist designed a data collection form that included 
patient’s hospital number, date of birth, weight, gestation, diagnosis, drug prescribed and 
administered, date and route of administration, dose, frequency, and indication for use. In this 
study, unlicensed drugs referred to: (1) modifications to licensed drugs, for example, 
preparation of a total parenteral nutrition infusion by a hospital pharmacy’s aseptic service 
unit, (2) use of “special” formulations of licensed drugs produced under a manufacturing 
license, that is, suspension of a drug licensed in a solid dose form but formulated into a liquid 
preparation by a “specials” manufacturer, for example, dexamethasone, and (3) “new” drugs, 
for example tolazoline injection for the treatment of pulmonary hypertension. Off- label, that 
is, drugs used outside the terms of their product license, included the administration of a drug 
to a patient of an age not covered by the product license, in a dose other than that specified in 
the license, by an alternative route, or for an indication not included in the license. In this 
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study, 70 patients were admitted to the neonatal intensive care unit (NICU) at a hospital in 
the United Kingdom during the study period, with 49 babies being premature and requiring 
intensive care. The median gestational age was 33 weeks. The babies received a total of 455 
prescriptions episodes (each episode being a course of a drug or a single once-off dose). Of 
the prescriptions, 161 (35.4%) were licensed drugs, 45 (9.9%) were unlicensed drugs, and the 
remaining 249 (54.7%) were drugs used in an off- label manner. Further, 63 (90%) babies 
received at least one unlicensed or off-label drug. The unlicensed drugs fell into three 
categories, namely, (a) modification, which included drugs such as morphine, 
phenobarbitone, dopamine, and total parenteral nutrition (all prepared in the hospital 
pharmacy), (b) the “new” drug prepared by “special” manufacturer included caffeine, and (c) 
“special” formulation of licensed drugs, which included drugs such as chloral hydrate, 
dexamethasone, adrenaline, and spironolactone. It was found that off- label use was far more 
common than unlicensed drug use in this population and included drugs like morphine, folic 
acid, benzylpenicillin, vitamin K, flucloxacillin, albumin, and gentamycin. Similarly, at the 
RCWMCH, where the present study was conducted, it is also common practice for 
prescribers to order “special” manufactured drugs like caffeine (used as a respiratory 
stimulant) and sildenafil (for pulmonary hypertension). In addition, drugs such as gentamycin 
are also prescribed outside its licence terms, for example, as part of a bowel cocktail in 
patients with gastro-enteritis.  
It is interesting to note further, that according to Ghaleb et al. (2010), drugs are often 
used off-license, leading to less clear dosing guidance. In addition, a small mistake, which 
might be tolerated in adults, can have significant consequences in a young child. 
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2.7 Parameters of the current study 
2.7.1 Preamble 
The rationale for the study was driven by the observance of the inconsistencies in prescribing 
practice and the large number of prescribing errors both by junior and senior prescribers at 
RCWMCH  
The research studies, as highlighted in the literature review above, indicated the prevalence of 
prescribing errors, irrespective of the volume of prescriptions. For example, the study carried 
out in a 15-bed paediatric cardiac ward and four bed cardiac ICU at University Hospital in 
Wales (Wilson et al., 1998), showed a total of 441 error reports submitted during the 
24month period, of which prescribing errors accounted for 68%. Doctors, nurses and 
pharmacists all participated in reporting errors, a practice not readily observed in hospitals in 
South Africa. The study by Kozer et al. (2000) at the Hospital for Sick Children in Toronto, 
Canada, found that healthcare trainees were more likely to contribute to prescribing errors. 
Prescribing by junior doctors is not unique to that hospital setting. My own experience of 
working at the RCWMCH shows that some of the wards have junior doctors who are also 
involved in the process of prescribing. Moreover, as highlighted by the study carried out in 
Christchurch, New Zealand (Grimwood et al., 1983), there is a concern with incorrect 
prescribing of antibiotics, be it in regard to the dose, frequency, or incorrect choice of 
antibiotics. Another concern with regard to prescribing practice is that of drug disease 
interaction. The local study at the BHCD in Cape Town (Schaaf et al., 2009) illustrated the 
concern of low serum levels of RMP concentrations in children, the great majority who 
received the recommended standard dosage of 8 to 12mg/kg. Prescribers need to consider 
higher dosages for RMP, especially in a country like South Africa where serious cases of TB 
coupled with HIV-infected children is common. More studies and on-going education with 
 
 
 
 
44 
 
regard to prescribing for patients with HIV and TB are needed. Drug interactions are also to 
be taken into consideration, especially in situations where prescribers decide to change the 
therapeutic regimen, as shown in the study by Martinbiancho et al. (2007). One particular 
DDI of note in the current study is that of valproic acid and phenobarbitone, drugs commonly 
prescribed for epileptic children, which is used at the RCWMCH. Both drugs enhance each 
other’s toxicity and thus need close monitoring, a practice not always carried out. 
 
 
2.7.2 Research question 
The research question the proposed research study poses and sets out to answer is: are 
prescribers fully compliant with the legal prescription requirements, as set out by the 
Medicines and Related Substance Act 101 of 1965 (Medicines and Related Substance Act101 
of 1965, Regulations as amended, 2014:28), with regards to information relating to the 
prescriber, the patient, and the drug?  
 
2.7.3 Hypothesis 
The hypothesis of the proposed research study, which it sets out to prove, is that most 
doctors do not adhere to the Medicines and Related Substance Act 101 of 1965 (Medicines 
and Related Substance Act101 of 1965, Regulations as amended,2014:28)  when it comes to 
prescribing, with missing information outnumbering other types of errors. 
 
 
2.7.4 Aim 
The aim of the proposed research study is to identify the pattern of prescribing 
practice at RCWMCH. 
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2.7.5 Objectives 
 The objectives of the current research study are as follows: 
 to describe the type of prescribing errors and frequency thereof, 
 to describe the prescribing error frequency per different classes of drugs, 
 to identify potential drug-drug interactions (DDIs), 
 to identify potential) drug-disease interactions (DDiS), 
 to describe off-label (OL) prescribing, and 
 to identify some of the determinants of prescribing errors  
2.7.6 Expected outcomes 
 Increase in awareness of prescribing in accordance with legal requirements as 
per medicines and Related Substance Act 101 of 1965 
 Importance of rational medicine use in a paediatric hospital 
 Importance of medication error reporting  
 The need to continuously educate prescribers about the  writing style and 
decision-making process of  prescribing 
 Standardisation of the prescription charts  
 
 
 
 
 
 
 
 
46 
 
Chapter 3 
Materials and Method 
3.1 Study design, site, and population  
 The prospective, cross-sectional study took place at Red Cross War Memorial Children’s 
Hospital (RCWMCH) in Cape Town, in wards B1 (28 beds) and B2 (25 beds) (general 
medical wards) as well as in two specialty wards, that is, the Paediatric Intensive Care Unit 
(PICU) (20 beds) and ward G1 (oncology) (17 beds). The study involved doctors working in 
these wards over the period 1 July 2012 to 31 December 2012.  
 
3.2 Inclusion criteria and exclusion criteria 
Only in-patient prescriptions generated in the four above mentioned wards and drug items 
current at the time of prescribing were included in the study. Prescriptions from prescribers 
(that is, interns, senior house officers (SHOs), registrars, and consultants) affiliated to the 
RCWMCH were evaluated in the study. 
Prescriptions generated in the out-patient department (for acute and chronic 
conditions) and in the trauma surgical, cardiac, renal, and liver transplant wards as well as 
prescriptions written by a referring doctor from another hospital were excluded from the 
study. 
 
3.3 Sample size 
Incomplete information formed the basis of the most recurring type of prescribing errors, 
presumably occurring one and half times more frequently than all the other types of errors 
combined. Convenience sampling was used  during routine working hours. The sample size 
estimation was accomplished by assuming that incomplete information accounted for 60% 
(0.6) of all prescribing errors, with other types of prescribing errors assumed at 40% (0.4). 
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The average of the two proportions was calculated and equaled 0.5. The standardized or 
effect size was calculated based on a standard statistical formula, with the answer equaling 
0.4. The sample size was then calculated for a significant level of 5% and 80% power. The 
sample size obtained from this calculation equaled 98. Thus, a total sample size of 196 
prescriptions for the two groups, namely, junior and senior prescribers, was needed. I thus 
took 200 prescriptions as the sample size (Hicks, 2009). 
 
3.4. Parameters assessed 
The following parameters were assessed during the study: (1) prescribing errors, (2) potential 
drug interactions (DDIs), (3) potential drug-disease interactions (DDiS), and (4) off-label 
(OL) prescribing. Information related to parameters 1–4 were transferred into Excel and 
further analyzed using STATA 11, and (5). Weight-for-age (WAZ) nutritional status was also 
assessed. Mass of all the patients were converted into weight-for-age z-score (WAZ), using 
WHO (de Onis et al.,2006) child growth standards, measured via STATA 12. 
The first datasheet (see Appendix A) included biographical information, that is, the 
study number, folder number, time of assessment of prescription chart, date of birth, gender 
of the patient, and body weight. Clinical information, that is, ward location, current date, 
primary diagnosis, and co-morbid conditions were also included. Drugs were identified by 
numeric codes, with the drug items identified by the respective number(s) on the data sheet. 
 
3.5 Definitions and nomenclature used 
A list of definitions and terms used in this thesis is provided here, presenting the 
meanings of each as understood and used throughout this study.  
 
 
 
 
 
 
48 
 
3.5.1 Prescribing error 
For the purpose of this study, the definition of a prescribing error included failure to 
comply with the legal requirements for writing a prescription, that is, as per the definition 
used in the Medicines and Related Substance Act 101 of 1965(Medicines and Related 
Substance Act, 101 of 1965, Regulations as amended, 2014:28). A prescription is a medico-
legal document and requires being written up correctly; any deviation from this required 
format was recorded in this study as an error on the datasheet. The required medico-legal 
format means a prescription has to be written in legible print, stating the following: (a) name 
and signature of the prescriber, (b) name, gender, and admission number of the patient, (c) 
date of issue of the prescription, (d) the approved or proprietary name of the medicine, (e) the 
dosage form, (f) the strength of the dosage form and the quantity of the medicine to be 
administered, (g) instructions for the administration, (h) frequency, and (i) period of use. The 
study adhered to these requirements with regard to the prescriptions it considered.  
Any prescribing error noted was classified on the datasheet according to the type of 
error, including errors pertaining to  (1) incomplete or insufficient information, (2) legibility, 
(3) clarity, (4) use of abbreviations, (5) wrong name, (6) dose too high, (7) dose to low, (8) 
allergy, (9) wrong time, (10) wrong route, (11) wrong frequency, (12) wrong unit, (13) drug 
duplication, (14) alteration, (15) contra-indication, and (16) other. Thus, an expanded 
definition of prescribing error with regard to the selection of the drug for the patient, the dose, 
the strength, the route, the quantity, the indication, and the contraindications, were also 
included for the purpose of the study. Below, I clarify some of the descriptions in the list of 
errors.  
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3.5.2 Wrong name 
For some prescriptions, the prescriber indicated the wrong name of the medication, 
that is, a trade or brand name for a drug, for example, bactrim (a brand name) was written 
down and not the generic name, for example, co-trimoxazole. 
 
3.5.3 Legibility 
Some prescriptions were not written in legible print and were difficult to decipher and 
posed problems in terms of readability. 
 
3.5.4 Clarity 
Clarity was identified as a problem when no clear prescribing instructions were 
provided by the prescriber. For instance, an occurrence of non-clarity with regard to route of 
administration was recorded as a prescribing error. An example of this included a prescription 
for paracetamol, in which the prescriber indicated “po” (per oral) and “pr” (per rectum) as 
“po/pr” in the section for route of administration, thus not providing a clear instruction to the 
administering nurse.  
In some cases, alterations of prescriptions were observed, that is, a prescription for a 
drug item was changed by a prescriber (for example, a dose) prior to the administration of the 
drug, with the prescriber failing to draw a clear line through the altered prescription and 
omitting to write his or her name and signature next to the alteration on the prescription. In 
other cases, the prescriber changed the prescription (for example, to a different drug item or  
frequency of administration) after the initial drug item prescribed was already administered. 
These were also recorded as a type of prescribing error.  
 In other cases, the type of errors   under other type of errors, included prescriptions 
written by unauthorized prescribers (for example, restricted drug items) and prescriptions 
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including inappropriate drug items, that is, not the correct or best drug for the condition being 
treated.  
 
3.5.5 Allergy 
An allergy for a drug item was also included as a type of error, that is, in cases where 
a patient developed an adverse drug reaction on first exposure to the drug.  
 
3.5.6 Contra-indication 
Another type of error included contra-indications to a drug, for example, when the 
drug should not be used, as in one particular case when a drug should not have been 
prescribed due to a pre-existing condition. 
 
3.5.7 Potential drug-drug interactions  
Drugs with the potential to interact were listed by their respective number(s) on the 
datasheet. The interaction type included: (1) increase in absorption, (2) decrease in 
absorption, (3) increase in drug distribution, (4) decrease in drug distribution, (5) increase in 
metabolism, (6) decrease in metabolism, (7) increase in excretion, (8) decrease in excretion, 
and (9) other (that is, potential pharmacodynamic interactions). A brief description of the 
potential DDI was given and the interacting drug(s) listed using the numeric codes. 
3.5.8 Potential drug-disease interactions  
A drug item with the potential to exacerbate an existing disease was indicated on the 
datasheet according to numeric code; the type of DDiS included potential clinical outcomes, 
that is, (1) cardiotoxicity, (2) nephrotoxicity, (3) hepatotoxicity, (4) ototoxicity, (5) blood 
disorders, (6) change in glucose levels, and (7) any other. A brief description of the potential 
DDiS were also given. 
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3.5.9 Off-label prescribing 
All off-label (OL) drug items were indicated by the relevant drug item number on the 
datasheet, the type of OL was described in terms of: (1) age, (2) formulation, (3) dose, (4) 
frequency, (5) route, (6) duration of treatment, and (7) other (such as a drug being prescribed 
for a condition for which it was not approved). 
The second datasheet (see Appendix B in this thesis) included information about the 
possible determinants of prescribing errors, including the level of experience of the 
prescriber, the day of the week, age of the patient, and location. Drug characteristics, such as 
drug formulations (that is, intravenous, intramuscular, oral, suppository, inhalation devices, 
and topical application) and the class of the drug (that is, gastrointestinal tract, blood system, 
cardiovascular, hormonal therapy, anti-infective agents, cancer therapy , musculo-skeletal 
system, nervous system, respiratory tract, and other (topical therapy)), the number of drugs 
prescribed, and the formulary status of drug (that is, formulary versus non-formulary drug) 
were also indicated on the datasheet (see Appendix B), to further identify the possible 
determinants of prescribing errors. These variables were all numerically coded (see Appendix 
B). For statistical analysis purposes, the variables were collapsed and numerically coded as 
follows:  
 Junior doctors (that is, interns and senior health officers (SHO) (1), versus senior 
doctors (that is, registrars and consultants) (2),  
 Weekday (1) versus weekend (2), 
 All patients aged below 12 months (1), versus 13–60 months (2),versus patients aged 
over 60 months (3),  
 Speciality wards (G1 and PICU) (1) versus general medical wards (B1and B2) (2), 
 Oral formulation (1) versus other formulations (that is, intravenous, intramuscular, 
suppository, inhalation, and topical) (2), 
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 Antibiotics (1) versus vitamins and minerals (2) versus other (that is, gastrointestinal, 
blood system, cardiovascular, hormonal, antifungal, antiviral, oncology, 
musculoskeletal, nervous system, and respiratory system) (3),  
3.5.10 Nutritional status 
The nutritional status for male and female patients for the various defined age 
categories in the different locations (wards) were assessed using the weight-for-age (WAZ) z-
score classification. The classification is based on WHO growth standards (de Onis et.al, 
2012), with classifications recorded as: overweight (WAZ >+2.00), normal weight (-
2.00<WAZ<+2.0), moderate underweight (-3.00<WAZ<-2.01), and severe underweight 
(WAZ<-3).  
 
 
3.6 Data collection 
A datasheet (see Appendix A) containing both biographical and clinical information about the 
patient and a datasheet indicating possible risk factor(s) variables (see Appendix B) were 
used to collect the relevant information by a pharmacist during daily routine ward rounds in 
two general medical wards (B1 and B2) and two speciality wards (PICU and G1) at 
RCWMCH. Data were collected from the respective patient(s) folders and from the 
prescription charts at their bedside(s). 
 
3.7 Methods of statistical analysis 
STATA Version 11 was used for the statistical analysis of this descriptive study. Data was 
entered into an Excel spreadsheet and then imported into STATA. Data analysis was 
performed by a biostatistician. Normality of numeric data was assessed, using the Shapiro-
Wilks test. The mean ± range or the median ± interquartile range and the odds-ratio (OR) 
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were calculated, as indicated. Where required, 95% Confidence Interval (CI) and means were 
estimated. Categorical data were reported as proportions.  
Univariate analyses and multivariate logistic regression were used to identify 
determinants (predictors) for prescribing errors. For these analyses, odds ratios, p-values, and 
confidence intervals (CI) were calculated. Variables were assessed for inclusion in the 
regression analysis based on the results of the univariate analysis. These variables included: 
level of experience of the prescribing doctor, class of drug, ward location, drug formulation, 
formulary/non-formulary drugs, age of the patient, time of the week when the prescription 
was boarded, and number of drugs prescribed per patient. Variables on univariate analysis 
with a p-value of less than 0.25 were selected for inclusion in the logistic regression model. 
The model was then re-rerun with only significant variables included. No major changes in 
the regression parameters were noted.  
3.8 Timeframe 
The study was conducted over a period of 6 months, with data collection taking place from 
July 2012 to December 2012. In this period, a total of 200 prescriptions were reviewed. Each 
prescription was assessed once only during routine daily ward rounds by a pharmacist.  
 
3.9 Ethics considerations 
Prior to conducting the study, approval was requested from and approved by the following 
institutions: 
1) the University of the Western Cape ( UWC) ethics committee, Reference number: 12/5/6, 
2) the University of Cape Town (UCT) Faculty of Health Sciences Human Research Ethics 
Committee, reference number: HREC.REF:315/2012, and 
3) the RCWMCH Research Committee, reference number R001/12. 
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The study was conducted according to the ethics requirements stipulated by the NDoH 
and the international Declaration of Helsinki. The information collected was kept confidential 
and saved in a safe file, which can only be accessed by the researcher. Patient confidentiality 
and privacy was maintained at all times. 
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Chapter 4 
Results 
4.1 Sample size and characteristics 
The total number of patients in the study sample was 200. Each patient’s prescription chart 
was reviewed once only over a six month period (July 2012–December 2012). The 
prescription chart comprised altogether 1 282 drug items for study over this period. The study 
took place in four different wards at the RCWMCH, namely, PICU, G1, B1, and B2. 
 
 
 
 
 
 
 
4.1.1 Age distribution 
 The 200 patients involved in the study had the following age distribution: 0–30 days 
(19 patients), 31 days–12 months (58 patients), 13–24 months (27 patients), 25–60 months 
(35 patients), 61–120 months (35 patients), and those aged above 120 months (26 patients). 
The median age was 22 months, the 25th quartile was 4.45 months, and the 75th quartile was 
78.25months.  
 
4.1.2 Presenting conditions 
During this study, the following conditions with occurrence were as follow: acute 
gastroenteritis (AGE) (19), acute lymphoblastic leukemia (ALL) (13), acute myeloid 
leukemia (AML) (5), acute promyelocytic leukemia (APL) (1), acute respiratory distress 
syndrome (ARDS) (5), asthma (6), burns (1), bilateral knee and right ankle effusion (1), 
bilateral myositis (1), bronchiolitis (1), Burkett lymphoma (2), congestive cardiac failure 
(CCF) (11), cellulites (1), gastro-oesophageal reflux disorder (GORD) (17), hepatitis (2), 
HIV positive (31), Haemophagocytic lymphohistocytosis (HLH) (1), Hodgkin’s lymphoma 
(1), hypothyroidism (1), haemoptysis (1), herpetic stomatitis (1), hypocalcemia (1), 
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hypokalemia (2), idiopathic thrombocytopenic purpura (ITP) (1), lower respiratory tract 
infection (LRTI) (23), myocardial infarction (MI) (1), myocarditis (1), meningitis (1), 
necrotic enterocolitis (2), neutropenic fever (NF) (8), otitis media (OM) (4), oral thrush (1), 
patent ductus arteriosis ligation (2), pneumocystic jiroveci pneumonia (PJP) (4), primary 
brain tumour (1), pneumonia (14), sickle cell anaemia (2), sepsis (23), seizures (6), septic 
shock (1), systemic fungal infection (1), tuberculosis (TB) (20), tetralogy of fallot (TOF) (1), 
thrombo-embolism (1), tinea capitis (1), upper respiratory tract infection (URTI) (6), urinary 
tract infection (UTI) (1),ventricular septal defect (VSD) (3), haematuria (1), and pulmonary 
artresia(1). 
Table 1, following, depicts the age range of patients in the sample and shows 
occurrence of the corresponding conditions that were most prevalent (that is, four and more 
conditions). 
 
  
 
 
 
 
57 
 
Table 1: Age range of the patient(s) with the occurrence of the corresponding conditions 
Condition Age range  
(in months) 
Occurrence 
of condition 
Acute gastroenteritis (AGE) 0.5–120  19 
Acute lymphoblastic leukemia (ALL) 5–60  13 
Acute respiratory distress syndrome (ARDS) 2–116   5 
Asthma 0.5–9   6 
Congestive cardiac failure (CCF) 0.16–156  11 
Eczema 1–131  10 
Epilepsy 11–148   6 
Failure to thrive (FTT) 0.6–143  34 
Gastro-oesophageal reflux disorder (GORD) 2.3–156  17 
HIV infection 0.5–176  31 
Lower respiratory tract infection (LRTI) 0.5–163  23 
Neutropenic fever (NF) 13–120   8 
Otitis media (OM) 0.5–163   4 
Pneumocystic jiroveci pneumonia (PJP) 0.5–23   4 
Pneumonia 0.4–148  14 
Sepsis 0.5–151  23 
Seizures 0.5–60   6 
Tuberculosis (TB) 0.5–176  20 
Upper respiratory tract infection (URTI) 0.9–87   6 
Total — 260 
 
Table 2, following, indicates the number of patients with the corresponding number of 
conditions, the total number of drugs prescribed, and the mean and median number of drugs 
prescribed per patient. As the number of conditions presented increased from one to three, the 
mean and median number of drugs increased. Similarly, the mean and median number of 
drugs prescribed for patients presenting with four to five conditions also increased 
correspondingly. One patient with six and another with seven conditions had a mean and 
median of 12 and 10 drugs prescribed, respectively. 
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Table 2: Total, mean, and median number of drugs prescribed for the 200 patients  
in the study sample 
   *
These patients presented with a combination of various conditions,  
for example, one patient presented with seven conditions.  
Totals are presented in the final row. 
 
Table 3, following, indicates the number of scripts, as well as the numbers for 
minimum, maximum, and mean number of conditions presented. Prescriptions with five, six, 
and seven drugs prescribed had a maximum of four and a median of two conditions.  
Prescriptions with the higher number of drugs prescribed, interestingly, had a lower 
maximum and a lower and /or same median number of conditions as prescriptions with lesser 
numbers of drugs prescribed; for example, prescriptions with 13 drugs prescribed had a 
maximum and median of three conditions and prescriptions with 16 drugs prescribed had a 
maximum of three and a median of two conditions. 
  
No. of 
conditions 
presented
 
No. of 
patients* 
Total no. 
of drugs 
prescribed 
Mean no. of 
drugs prescribed 
per patient 
Median no. of 
drugs prescribed 
per patient 
1   57      223     3.9    3 
2   76      484     6.4    6 
3   46      391     8.5    9 
4   15      123     8.2    8 
5      4        39     9.8       8.5 
6      1       12 12   12 
7     1       10 10   10 
          28 200  1 282 — — 
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Table 3: Number of conditions and scripts with corresponding number  
of drugs prescribed 
No. 
of drugs 
prescribed 
No. of scripts 
Minimum no. 
of conditions 
Maximum  
no.  of 
conditions 
Median  
no. of 
conditions 
   1    3 1  1 1 
   2 14 1  2 1 
   3 28 1  3 1 
   4 22 1  4 2 
   5 22 1  4 2 
  6 18 1  4 2 
  7 31 1  4 2 
   8 12 1  5 2 
  9 12 2  5 3 
10 12 1  4 3 
11   8 2  7 3 
12 11 2  6 2 
>12   7 7 11 __ 
 
 
4.1.3 Nutritional status 
Out of the 200 patients studied, 122 (61.0%) had a normal body weight, 40 (20%) 
were severely underweight, 25 (12.5%) were moderately underweight, and 13 (6.5%) were 
overweight. Table 4, following, indicates the number of patients in the categories of 
nutritional status and age. 
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Table 4: Nutritional status for male and female patients in the various defined  
age categories 
Nutritional Status 
Indicators Gender 
Age Category 
Total 
Percentage 
(%) *1.1 1.2 1.3 2 3 4 
Overweight M   1   1   0   1   1   0 
  13    6.5 
(WAZ>+2.00) F   2   3   3   1   0   0 
Normal weight M   5 16    6   9  15   5 
122     61.0 
(-2.00<WAZ<+2.00) F   4 12   7 15 14 14 
Moderate underweight M   1   4   4   0   1   4 
  25     12.5 
(-3.00<WAZ<-2.01) F   3   4   1   2    0   1 
Severe underweight M   1 12   3   3   3   0 
  40      20.0 
(WAZ<-3) F   2   6   3   4   1   2 
Total 
 
19 58 27 35 35 26 200 100 
*
1.1 = 0–30 days; 1.2 = 31 days–12 months; 1.3 = 13–24 months;  
2 = 25–60 months; 3 = 61–120months; 4 = >120 months 
 
Table 5, below, shows the nutritional status for male and female patients per ward. 
 
Table 5: Nutritional status for male and female patients in different locations (wards) 
Nutritional Status 
Indicators 
Gender 
Location 
Total 
Percentage 
(%) PICU G1 B1 B2 
Overweight M  1  1   0   2 
  13    6.5 
(WAZ>+2.00) F  0   2   3   4 
Normal weight M  8 10 25 13 
122 61.0 
(-2.00<WAZ<+2.00) F      16 14 13 23 
Moderate underweight M   2   2   5   5 
  25 12.5 
(-3.00<WAZ<-2.01) F   2   1   5   3 
Severe underweight M   2   0 12   8 
  40 20.0 
(WAZ<-3) F   6   0   5   7 
Total — 37 30 68 65 200        100 
Percentage (%) —    18.5 15 34 
   
32.5 100 — 
 
Table 6, following, shows the conditions, nutritional status, and treatment regimen for 
severely underweight patients. 
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Table 6: Conditions, nutritional status, and treatment regimen in severely  
underweight patients 
Patient Condition 
*WAZ 
(z-score) 
Name of drug 
  1 Chronic gastroenteritis (CGE) -3.06 Multivitamin 
 
Pneumonia 
 
Cholestyramine 
 
Down’s syndrome 
 
Gentamycin 
 
  
 
Amoxycillin 
 
  
 
Zinc 
 
  
 
Folic acid 
 
  
 
Formoterol 
  2 Septic shock -3.29 Folic acid 
 
Acute renal failure  
 
Paracetamol 
 
Microcytic anaemia 
 
Pyrazinamide 
 
HIV- infection 
 
Ethambutol 
 
Tuberculosis (TB) 
 
Rifampicin + isoniazid 
 
  
 
Multivitamin 
 
  
 
Ampicillin 
 
  
 
Diazepam 
 
  
 
Clonidine 
 
  
 
Pyridoxine 
 
  
 
Cotrimoxazole 
 
  
 
Nystatin 
 
  
 
Acetazolamide 
 
  
 
Prednisone 
  3 Pneumonia -3.04 Omeprazole 
 
Gastro oesophageal reflux disorder (GORD) 
 
Cotrimoxazole 
 
  
 
Vidaylin 
 
  
 
Vitamin D 
 
  
 
Prednisone 
 
  
 
Formoterol solution 
 
  
 
Normal saline 
  4 Pneumonia -5.97 Zinc  
 
  
 
Folic acid 
 
  
 
Phenobarbitone 
  5 Gastro Oesophageal Reflux Disorder 
(GORD) 
-7.76 Vidaylin 
 
  
 
Vitamin D 
 
  
 
Omeprazole 
  6 Necrotising enterocolitis -5.4 Meropenem 
 
Anaemia 
 
Fluconazole 
 
Hypoglycemia 
 
Nystatin 
 
Hypokalemia 
 
Hydrocortisone 
 
Laparotomy 
 
Zidovudine 
 
  
 
Paracetamol 
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Vancomycin 
 
  
 
Cimetidine 
  7 Lower respiratory tract infection (LRTI) -7.35 Ciprofloxacin 
 
Pneumonia 
 
Normal saline 
 
Failure to thrive (FFT) 
 
Paracetamol 
 
Gastro oesophageal reflux disorder (GORD) 
 
Omeprazole 
 
Normocytic anaemia 
 
Folate 
 
  
 
Multivitamin 
 
  
 
Zinc 
 
  
 
Salbutamol 
 
  
 
Morphine 
  8 Pneumonia -16.58 Paracetamol 
 
  
 
Multivitamin 
 
  
 
Diazepam 
 
  
 
Piptazobactam 
 
  
 
Amikacin 
  9 Hypothyroidism -6.62 Prednisone 
 
Pneumonia 
 
Ferrous Gluconate 
 
  
 
Multivitamin 
 
  
 
Co-trimoxazole 
 
  
 
Eltroxin 
 
  
 
Duocal 
 
  
 
Azithromycin 
 
  
 
Folate 
10 Acute gastro enteritis (AGE) -3.16 Abacavir 
 
Hepatotoxicity  
 
Lopenavir+Ritonavir 
 
HIV- infection 
 
Lamivudine 
 
  
 
Ritonavir 
 
  
 
Rifampicin & Isoniazid 
 
  
 
Ofloxacin 
 
  
 
Co-trimoxazole 
 
  
 
Omeprazole 
 
  
 
Multivitamin 
 
  
 
Zinc 
 
  
 
Hydrocortisone 
 
  
 
Ethambutol 
 
  
 
Paracetamol 
 
  
 
Tilidine hydrochloride 
11 Tuberculosis (TB) -4.48 Paracetamol 
 
  
 
Acetazolamide 
 
  
 
Multivitamin 
 
  
 
Zinc 
 
  
 
Rifampicin+Isoniazid 
 
  
 
Pyrazinamide 
 
  
 
Ethionamide 
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Prednisone 
 
  
 
Phosphate 
 
  
 
Furosemide 
12 Failure to thrive (FFT) -13.69 Sorbitol 
 
Chronic Lung Disease (CLD) 
 
Multivitamin 
 
Haemolytic anaemia 
 
Omeprazole 
 
  
 
Folic acid 
 
  
 
Zinc 
 
  
 
Paracetamol 
 
  
 
Ferrous gluconate 
13 Pneumocystis jerovici pneumonia (PJP) -5.99 18% sodium chloride 
   
Co-trimoxazole 
 
  
 
Phosphate 
14 
Gastro Oesophageal Reflux Disorder 
(GORD) -5.53 Spironolactone 
 
Congestive Cardiac Failure (CCF) 
 
Furosemide 
 
  
 
Vidaylin 
 
  
 
Vitamin D 
 
  
 
Nevirapine 
 
  
 
Omeprazole 
 
  
 
Co-trimoxazole 
15 HIV- infection -4.27 Tilidine HCL 
 
Microcytic anaemia  
 
Cimetidine 
 
Pancreatitis 
 
Paracetamol 
 
Pyelonephritis 
 
Cefotaxime 
16 HIV- infection -5 Multivitamin 
 
Eczema 
 
Folic acid 
 
  
 
Zinc 
 
  
 
Vitamin D 
 
  
 
Clotrimazole 
 
  
 
Aqueous Cream 
 
  
 
Lopenavir+Ritonavir 
 
  
 
Lamivudine 
 
  
 
Abacavir 
 
  
 
Co-trimoxazole 
 
  
 
Emulsifying ointment 
17 
Gastro Oesophageal Reflux Disorder 
(GORD) 
-12.79 Multivitamin 
 
Dystonia 
 
Paracetamol 
 
Failure to thrive (FFT) 
 
Zinc 
18 Tuberculosis (TB) -5.84 Paracetamol 
 
Fever 
 
Multivitamin 
 
  
 
Rifampicin+Isoniazid 
 
  
 
Pyrazinamide 
 
  
 
Ethionamide 
 
  
 
Zinc 
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Prednisone 
 
  
 
Hyoscine-N-
Butylbromide 
 
  
 
Folic acid 
19 Seizures -3.26 Rifampacin + Isoniazid 
 
Tuberculosis (TB) 
 
Sodium Valproate 
 
  
 
Hydrocortisone 
 
  
 
Pyrazinamide 
 
  
 
Ethionamide 
 
  
 
Prednisone 
 
  
 
Paracetamol 
20 HIV- infection -3.1 Multivitamin 
 
Lower respiratory tract infection (LRTI) 
 
Zinc 
 
  
 
Folic acid 
 
  
 
Lamivudine 
 
  
 
Abacavir 
 
  
 
Lopenavir+Ritonavir 
 
  
 
Nystatin 
 
  
 
Omeprazole 
 
  
 
Cefuroxime 
21 Necrosis -4.896 Meropenem 
 
  
 
Zidovudine 
 
  
 
Nystatin 
 
  
 
Fluconazole 
22 Cerebral palsy (CP) -4.09 Penicillin G 
 
Lower respiratory tract infection (LRTI) 
 
Gentamycin 
 
  
 
Zidovudine 
 
  
 
Nystatin 
 
  
 
Paracetamol 
 
  
 
Multivitamin 
23 Tuberculosis (TB) -3.23 Prednisone 
 
Fever 
 
Rifampicin+Isoniazid 
 
Failure to thrive (FFT) 
 
Pyrizanimide 
 
  
 
Ethionamide 
 
  
 
Multivitamin 
 
  
 
Zinc 
 
  
 
Acetazolamide 
 
  
 
Furosemide 
 
  
 
Paracetamol 
 
  
 
Folic acid 
 
  
 
Sodium chloride 
24 Tuberculosis (TB) -5.13 Pyrazinamide 
 
Sepsis 
 
Rifampicin+Isoniazid 
 
  
 
Ethambutol 
 
  
 
Zinc 
 
  
 
Cefuroxime 
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Clonidine 
25 Herpetic Stomatitis -5.18 Allopurinol 
 
Asthma 
 
Cotrimoxazole 
 
  
 
Prednisone 
 
  
 
Sodium chloride 
 
  
 
Paracetamol 
 
  
 
Atrovent:berotec:saline 
 
  
 
Ceftriaxone 
 
  
 
Acyclovir 
26 Primary brain tumour -3.69 Rifampicin + isoniazid 
 
Coartation of aorta 
 
Pyrazinamide 
 
  
 
Ethionamide 
 
  
 
Prednisone 
 
  
 
Paracetamol 
 
  
 
Zinc 
 
  
 
Acyclovir 
27 Acute gastro enteritis (AGE) -3.87 Zinc 
 
  
 
Multivitamin 
 
  
 
Potassium Chloride 
 
  
 
Cholestyramine 
 
  
 
Gentamycin 
 
  
 
Ampicillin 
28 Congestive Cardiac Failure (CCF) -3.85 Multivitamin 
 
Failure to thrive (FFT) 
 
Folic acid 
 
  
 
Spironolactone 
 
  
 
Sodium chloride 
 
  
 
Fluorometholone 
29 Lower respiratory tract infection (LRTI) -4.1 Amoxycillin 
 
  
 
Propranolol 
30 Upper respiratory tract infection (URTI) -3.38 Multivitamin 
 
Failure to thrive (FFT) 
 
Zinc 
 
  
 
Amoxycillin 
 
  
 
Amoxicyllin+clavulinic 
acid 
31 Upper respiratory tract infection (URTI) -4.01 Oxymetazoline 
 
Eye infection 
 
Zinc 
 
  
 
Multivitamin 
 
  
 
Folic acid 
 
  
 
Fluorometholone 
32 Pneumocystis jerovici pneumonia (PJP) -3.72 Cotrimoxazole 
33 Failure to thrive (FFT) -5.1 Multivitamin 
 
  
 
vitamin D 
 
  
 
Folic acid 
34 Otitis media (OM) -3.1 Paracetamol 
 
  
 
Cefuroxime 
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35 HIV- infection -3.01 Lamivudine 
 
  
 
Stavudine 
 
  
 
Efavirenz 
 
  
 
Cotrimoxazole 
 
  
 
Multivitamin 
36 Pneumocystis jerovici pneumonia (PJP) -6.57 
Heparin(low molecular 
weight) 
 
Lower respiratory tract infection (LRTI) 
 
Prednisone 
 
  
 
Cotrimoxazole 
 
  
 
Paracetamol 
37 Failure to thrive (FFT) -3.49 vitamin D 
 
  
 
Folic acid 
38 Oral candiadiasis -4.93 Paracetamol 
 
Fever 
 
Nystatin 
 
  
 
Fluconazole 
39 Failure to thrive (FFT) -7.11 Vidaylin 
 
  
 
Caffeine citrate 
 
  
 
Ferrous lactate 
 
  
 
Folic acid 
40 Hypertension -5.11 Multivitamin 
 
Staphyllococci skin infection 
 
Zinc 
 
  
 
Amlodipine 
 
  
 
Flucloxacillin 
 
  
 
Clonidine 
*WAZ = weight-for-age z-score (nutritional status indicator) 
 
As mentioned earlier, WHO (de Onis et al., 2012) defines a WAZ score greater than -3 as 
indicating a severe underweight for age. A total of 40 patients (20% of the study population) 
were severely underweight, as indicated by the weight-for-age (WAZ) z-score in the Table 6 
above. Z-cores allows clinical tracking of patients whose anthropometric classification lies 
beyond the measurable limits of the percentile range, as happens in the case of severely 
undernourished children (de Onis et.al, 2011). 
 
4.2. Prescribing patterns 
4.2.1 Prescriber category 
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From a sample of 200 prescriptions, 24 prescriptions were written by an intern, 47 
prescriptions by a senior health officer (SHO), 109 prescriptions by a registrar, and 20 by a 
consultant. For the number of drug items prescribed by the respective prescriber, see Table 7, 
which indicates the level of experience of doctor and the corresponding number of drug items 
prescribed. 
 
Table 7: Number of drug items prescribed per prescriber category 
Level of experience of prescriber No. of drug items prescribed 
Intern   114 
SHO   291 
Registrar   753 
Consultant   124 
Total 1 282 
 
 
4.2.2 Drug distribution 
A total of 1 282 drug items were prescribed collectively by all the prescribers in the 
sample. Table 8indicates the number of prescription charts (middle row) with the 
corresponding number of drug items prescribed (top row). 
 
Table 8: Number of prescription charts classified according to the number of 
drugs prescribed per prescription chart 
No. of drugs 
prescribed 
(A) 
1   2   3   4   5    6    7   8   9   10 11  12 13 14 15 16 
Prescription 
charts 
(B) 
3 14 28 22   22   18   31 12   12   12  8  11   2  3  0  2 
Total no. 
of drugs 
(A) x (B) 
3 28 84 88 110 108 217 96 108 120 88 132 26 42  0 32 
Total (B) = 200; Total [(A) × (B)] = 1 282 
 
4.2.3 Ward distribution 
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The total and mean numbers of drugs prescribed per location (ward) and the 
corresponding number of patients treated in the respective ward is illustrated in Table 9. 
In the sample, 30 of the 200 (15%) patients had 156 (12%) of the total number (1 282) 
of drugs prescribed in G1. In PICU, 37 patients (18.5%) had 272 (21.7%) of the total number 
of drugs prescribed. In the two medical wards, namely, B1, 68 patients (34 %) had 470 
(36.7%) drugs prescribed, while in B2, 65 patients (32.5%) had 384 (30%) drugs prescribed. 
 
 
 
Table 9: Distribution of drug items as per number of patients in the four  
different wards 
Ward No.  
of patients 
No.  
of drugs  
prescribed 
Mean no.  
of drugs  
prescribed 
PICU   37    272 7.35 
G1   30    156 5.20 
B1   68    470 6.93 
B2   65    384 5.89 
Total 200 1 282 6.34  
 
 Table 10, below, shows the distribution of drug items prescribed by the various 
prescribers, with each shown as a category of prescriber. 
 
Table 10: Distribution of drug items prescribed per location as per prescriber category 
Level of experience 
of doctor 
No. of drug items 
prescribed 
PICU G1 B1 B2 
Intern    114    0    0   57   57 
SHO    291    8    0 147 136 
Registrar    753 215 109 254 175 
Consultant    124   49   47   12   16 
Total 1 282 272 156 470 384 
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Among the prescribers, the registrars were responsible for prescribing the most 
number of drug items in all four wards, as reflected in Table 7 above. Interns did not take 
responsibility for prescribing in the two specialty wards, namely, PICU and G1, as no interns 
are assigned to these wards at the RCWMCH. SHO’s took responsibility for prescribing in 
PICU but not in ward G1. 
4.2.4 Distribution of drug items: Week day versus weekend 
 The study compared distribution of drugs in terms of week day versus weekend and 
genral medical versus specialty wards. Table 11 below shows the result of this comparison. 
 
Table 11: Comparison of drug distribution: Week versus weekend in general medical 
wards versus specialty wards 
Location 
Week Weekend  
Total 
No. % No. % 
Speciality wards  
(PICU and G1) 
   355   35   70   27  425 
General medical wards  
(B1 and B2) 
   662   65 190   73  852 
Total 1 017 100 260 100 1 277
* 
Percentage (%) 80 20 100 
*
Five prescription items did not have a physical date for the starting date  
of prescribed item, thus no date/day for the item in question was allocated;  
hence a sample size of  1 277 drug items (and not 1 282) for week versus  
weekend comparison with regards to drug distribution. 
 
4.2.5 Distribution of drug items according to age of patient 
Table 12, below, reflects the number of patients in the respective wards and the total 
and mean numbers of drugs prescribed according to patient age. Approximately 25% of the 
total number of drugs was prescribed for the 0–30 days age group, and approximately 10% of 
the total number of drugs prescribed for the older children, that is, children aged 10 months 
and over. The 13–24 months, 25–60 months, and 61–120 month categories showed a similar 
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pattern with regard to drug distribution, that is, 16%, 17.5%, and approximately 19%, 
respectively, of all drugs prescribed. 
 
 
 
Table 12: Distribution of drug items according to patient age 
Age of 
patient
* 
Total 
no. of 
patients 
No. of drugs 
prescribed 
No. of patients 
in ward 
 
  
   
PICU G1 B1 B2 
Total Mean 
   1.1   44   317 7.20   8   1 15 20 
   1.2   30   164 5.47   6   1 15   8 
   1.3   27   210 7.78   7   1 10   9 
2   37   225 6.08   4   7   9 17 
3   37   243 6.57   5 13 10   9 
4   25   123 4.92   7   7   9   2 
— 200 
1 282 
 
6.3 37 30 68 65 
*
1.1 = 0–30 days; 1.2 = 31 days–12 months; 1.3 = 13–24 months;  
2 = 25–60 months; 3 = 6–120 months; 4 = >120 months 
 
Table 13, following, shows the distribution of drug items prescribed according to 
formulation. 
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Table 13: Distribution of drug items according to formulation 
Formulation 
Drug items prescribed 
 
No. 
 
% 
Intravenous  151 11.77 
Intramuscular       4    0.31 
Oral   991   77.30 
Suppository       0 0 
Inhalation     21     1.63 
Topical     64    4.99 
Other     51    4.00 
Total 1 282 100 
 
 Table 14, shows the distribution of drugs prescribed according to the class of drugs. 
 
Table 14: Distribution of drug items according to class of drugs 
Class of drug 
Drug items prescribed 
 
No. % 
Antibiotics   256   20.00 
Antifungals     56     4.37 
Antivirals   121     9.43 
Other   438   34.16 
Nervous system   155   12.09 
Cardiovascular     78  6.08    
Hormonal     60     4.68 
Gastrointestinal     44     3.43 
Respiratory system     35     2.73 
Oncology    19      1.48 
Musculo-skeletal    14      1.09 
Blood system      6       0.47 
Total 1 282 100 
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4.3 Prescribing errors 
4.3.1 Frequency and type of errors 
The total number of drugs prescribed for the 200 prescriptions reviewed equalled 1 
282. Incomplete information was the most common type of error found (65.6%), followed by 
the wrong drug name, and use of abbreviations in place of generic names. Under other type of 
prescribing errors, errors such as inappropriate drug and unauthorised prescriber recurred. All 
other errors occurred at a frequency of less than 5%. Prescribed information (that is, drug 
name, strength, dose, route, frequency, formulation, and period), including the prescribers 
name and signature not easy to read on the prescriptions reviewed were problematic in terms 
of legibility, with the prescription(s) for the drug item(s) thus regarded as a prescribing error. 
A prescription in which instructions were not clearly stated, that is, in terms of strength, dose, 
route, frequency, formulation, and period was regarded as a clarity type of prescription error. 
An example of this is paracetamol having been prescribed as both per oral (po) and per 
rectum (pr) in the section for route of administration, indicated on that particular prescription 
as “po/pr”. In the case of a patient with a documented allergy for a drug item being 
inadvertently prescribed that drug, this was regarded as constituting a prescribing error. 
 Table 15, following, shows the frequency of prescribing errors found in the sample 
studied. The type of error identified and its frequency is provided. Incomplete information 
was observed as the most frequent type of error in most cases, followed by wrong name and 
use of abbreviations instead of generic name of drug. Allergy and contra-indication to a 
medicine were the least occurring type of error, as observed in this study. Prescribing errors 
involving the dose(s), including both high and low doses, occurred infrequently and 
prescribing errors with regards to the route of administration, frequency and the unit of 
strength of the medicine, occurred less frequently 
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Table 15: Frequency of prescribing errors 
Type of error
 
 
Frequency of error per drug item 
95% CI 
 
No. of errors 
 
 
N (%) 
 
Incomplete information   841 65.6 62.9–68.2 
Wrong name
* 
  216 16.8 14.8–19.0 
Abbreviations   146 11.3 9.7–13.2 
Legibility
* 
    57  4.4 3.4–5.7 
Clarity
* 
    42  3.3 2.4–4.4 
Alteration
* 
    32  2.5 1.7–3.5 
High dose     16  1.2 0.7–2.0 
Low dose     15  1.1 0.6–1.9 
Other
*
     10  0.8 0.4–1.4 
Wrong route      8  0.6 0.3–1.2 
Duplication      5  0.4 0.2–1.1 
Wrong frequency      6  0.5 0.2–1.0 
Wrong unit      4  0.3 0.1–0.8 
Allergy
*
      3  0.2 0.0–0.7 
Contra-indication       1  0.1 0.0–0.4 
Total 1 402         109 — 
*
Refer to Chapter 3 on Materials and Methods of this thesis  
for definitions of these terms. 
 
Any drug item can have one or more prescribing errors and the same pertained to those 
reviewed in this study. The total number of prescribing errors in the entire sample was 1 402. 
The overall error rate for prescribing errors was 1.09 (that is, the overall error rate = 1.09, 
thus the frequency is 109% in Table 15 above). This is illustrated by the formula Y = X/N, 
where Y is the overall prescribing error rate, X the total number of prescribing errors (1 402), 
and N the total number of prescribed drug items (1 282). 
 
4.3.2. Error frequency: Different classes of drugs 
 Table 16, following, shows the frequency of prescription errors for drug items 
prescribed by different classes of drugs. 
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Table 16: Error frequency for prescribed drug items by different classes of drugs 
Class of drug 
Total no.s 
of prescribed 
drug items 
No. of drug items 
with one or more 
prescribing error 
% 
Any error 
95 CI 
Antibiotics  256 192 75.0 (69.3–80.2) 
Antifungals     56   40 71.4 (57.8–82.7) 
Antivirals  121   82 67.8 (58.7–76.0) 
Other  
(vitamins and minerals) 
 438 305 69.6 (65.0–73.9) 
Nervous System  155  118 76.1 (68.6–82.6) 
Cardiovascular     78    61 78.2 (67.4–86.8) 
Hormonal     60    46 76.7 (64.0–86.6) 
Gastro-intestinal (GI)     44    38 86.4 (72.6–94.8) 
Respiratory system     35    21 60.0 (42.1–76.1) 
Oncology     19    11 57.9 (33.5–79.7) 
Musculo-skeletal     14    11 78.6 (49.2–95.3) 
Blood system       6      4 66.7 (22.3–97.7) 
Total 1 282 929 — 
 
There were 929 drug items with any type of error. The number of drug items without 
any type of prescribing errors was 353.This equates to 72.5% of all prescribed drugs 
with at least one prescribing error. 
Antibiotics were prescribed for conditions such as pneumonia, urinary tract infections (UTI), 
meningitis, sepsis, TB, and HIV-related conditions. Antifungals were prescribed mostly for 
HIV-related conditions such as severe thrush. Antivirals were commonly prescribed for CMV 
infections or herpes. Vitamins and minerals were prescribed as part of the WHO’s 10 steps 
for treating malnutrition (WHO, 1999). The routine prescription of zinc for diarrhoea and 
pneumonia is well known. Analgesics, sedatives, and anti-epileptics were prescribed for their 
relevant conditions (that is, fever, epilepsy, pain, anxiety, and post-operative treatment, 
respectively). Children with heart disease, congenital or acquired, were treated with anti-
failure medication as needed. Prednisone is often prescribed for its anti-inflammatory 
properties, for example, in asthma, TB, and meningitis. Proton pump inhibitors, for example, 
 
 
 
 
75 
 
omeprazole and cimetidine were commonly prescribed in patients with suspected or proven 
gastro-oesophageal reflux disorder (GORD). Nebulising agents like atrovent, salbutamol, and 
hypertonic saline were prescribed for asthma and bronchiolitis. Oncology drugs were mostly 
prescribed by haem-oncologists. Musculo-skeletal agents like ibuprofen and aspirin were 
prescribed for pain and inflammation. Blood system medication was mostly prescribed to 
known haemophiliacs and oncology patients. 
 
4.3.3. Error frequency: Location/ward      
 Table 17, below, shows the frequency for prescription errors by location or ward, with 
numbers for drug items prescribed and drug items with one or more prescribing errors 
recorded. 
 
Table 17: Error frequency for prescribed drug items by location/ward 
Location/ward 
Total no. of 
prescribed 
drug items 
No. of drug items 
with one or more 
prescribing errors 
% 
Any error 
95 CI 
PICU: specialty ward   272 209 76.8 (72.2–82.5) 
G1: Oncology ward   156 140 89.7 (83.2–93.6) 
B1: Medical ward   470 342 72.7 (68.3–76.6) 
B2: Medical ward   384 238 61.9 (56.8–66.7) 
Total 1 282 929 — 
 
G1 (the oncology ward) had a higher percentage of drugs with prescribing errors, 
compared to the other wards. There were significantly fewer drug items with prescribing 
errors in B2, the medical ward, compared to the other wards.  
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4.3.4 Error frequency by prescriber category 
Consultants had significantly more prescribing errors than all the other prescribers. 
Senior doctors (registrars and consultants) committed significantly more prescribing errors 
than did junior doctors (interns and SHO’s), that is, 78.3% of all drug items prescribed by 
senior doctors had at least one error versus 59.8% by junior doctors, hence the risk ratio of 
1.3 (95% confidence interval: 1.2-1.4), p<0.0001. Table 18, below, shows the error frequency 
for prescribed drug items by level of experience of prescribing doctor. 
 
Table 18: Error frequency for prescribed drug items by level of experience of doctor 
Qualification of prescribers 
Total no. of 
prescribed 
drug items 
No. of 
drug items with 
one or more 
prescribing 
error 
% 
Any error 
95% CI 
Intern    114   58 50.9 (41.3–60.4) 
SHO    291 184 63.2 (57.4–68.8) 
Registrar    753 579 76.9 (73.7–79.9) 
Consultant    124 108 87.1 (79.9–92.4) 
Total 1 282 929 — 
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4.3.5 Error frequency: Weekday versus weekend 
No significant difference for occurrence of prescribing errors was found for weekday 
and weekend. A missing date was classified as missing information (that is, for 
prescriptions with no starting date indicated for a newly generated prescription) and 
observed as a type of prescribing error. Table 19, below, shows the error frequency 
for prescribed drugs in terms of weekday versus weekend. 
 
Table 19: Error frequency for prescribed drug items: Weekday versus weekend 
Day of prescription 
Total no. 
of prescribed 
drug items 
No. of 
drug items with 
one or more 
prescribing error 
% 
Any error 
95 CI 
Weekday  1 017 752 73.9 (71.1–76.7) 
Weekend     260 172 66.1 (60.0–71.9) 
No day recorded  
(no physical starting date  
written in by prescriber,  
i.e., missing information,  
a type of prescribing error) 
       5      5  100 
Total 1 282 929 — 
 
 
4.3.6 Error frequency: Age of patient 
The study looked at frequency of prescribing errors in terms of patient age. 
Table 20, following, shows this in terms of child patient age ranging from 0–30 days up to 
61–120 months as well as the figures for drug items prescribed and prescribing error. 
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Table 20: Error frequency for prescribed drug items by age of patient 
Age of patient 
Total no. 
of prescribed 
drug items 
No. of 
drug items 
with one or more 
prescribing 
error 
% 
Any error 
0–30 days (neonates)     317 212 66.9 
31 days–12 months (infants)     164 155 94.5 
13–24 months (toddlers)     210 153 72.9 
25–60 months  
(young children) 
    225 125 55.6 
61–120 months     243 141 58.0 
>120 months    123 143 — 
Total 1 282 929 — 
 
The percentage of prescribing errors was highest in the infant group (94.5%), even 
though only 12.8% drug items were prescribed in this age group, in comparison to the 24.7% 
drug items prescribed for neonates. The percentage of prescribing errors observed for 
neonates was 66.9%  
4.3.7 Error frequency: Formulation type 
The confidence interval for percentage of errors for oral and intravenous formulation 
was narrow, in comparison to the confidence interval for percentage of errors for intra-
muscular, inhalation, topical, and other formulations. A low number of drug items were 
prescribed in the intra-muscular, inhalation, topical, and other formulation group, compared 
to oral and the intravenous formulations group. Table 21, following, shows the error 
frequency for prescribed drug items by formulation, as found in the study. 
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Table 21: Error frequency for prescribed drug items by formulation 
Formulation 
Total no. 
of prescribed 
drug items 
No. of drug items 
with one or more 
prescribing error 
% 
Any error 
95 CI 
IV    151 127 84.1 (77.3–89.5) 
IM        4     0 0 (0–60.2) 
Oral     991 717 72.4 (69.5–75.1) 
Inhalation      21   13 61.9 (38.4–81.9) 
Topical      64   41 64.0 (51.1–75.7) 
Other      51   31 60.8 (46.1–74.2) 
Total  1 282 929 — 
 
4.3.8 Error frequency: Range of drug items prescribed per prescription chart 
No significant difference was found with regards to the range(s) of drug items per 
prescription chart. Table 22 shows the result for the search for error frequency for 
ranges of prescribed drugs per prescription. 
 
Table 22: Error frequency for range(s) of prescribed drug items per prescription 
No. of drug items 
Total no. 
of prescription 
charts 
No. of 
charts with one 
or more 
prescribing error 
% 
Any error 
95 CI 
1 to 4    67    43 64.2 (51.5–75.5) 
5 to 10  107    78 72.9 (63.4–81.0) 
>10   26    19 73.0 (52.2–88.4) 
Total 200  140 — 
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4.4. Potential drug-drug interactions  
 As discussed earlier in chapters one and two of this thesis, drug-drug interaction (DDIs) are a 
concern as regards prescribing errors, especially for child patients, due to the latter’s 
undeveloped or immature organ systems which places them at greater risk for DDI errors 
where prescribing is concerned. In this study, the potential for pharmacodynamic drug-drug 
interactions (DDIs) were regarded as more likely to occur than pharmacokinetic drug-drug 
interactions (DDIs). Table 23 shows the overall potential for pharmacodynamic drug 
interactions (DDIs).  
 
 
Table 23: Potential pharmacodynamic drug-drug interactions 
Interaction type N (%) 95% CI 
Pharmacodynamic 20 (1.6) 2.4 
(see list below ) — — 
 
Table 24, following, describes the potential pharmacodynamic drug-drug interactions 
(DDIs) not necessarily recorded by the prescriber, but present. The combination drugs are 
separated as A and B categories in the table. The potential adverse reaction or event was 
listed in a separate column, with the studies that provided the information for the possible 
adverse effects also tabled. 
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Table 24: Description of potential pharmacodynamic drug-drug interactions (DDIs)  
(as indicated in Table 23 but not necessarily recorded by the prescriber, however, 
potentially present) 
Drug A Drug B Potential adverse event Reference(s) 
Chloroquine Co-trimoxazole Increased risk of potentially 
fatal skin reactions 
Uneke and Ogbonna, 
2009 
Furosemide Captopril Additive hypotensive effect Kopecky, Thomas and 
McAfee, 1987 
Ethionamide Isoniazid Additive neurological effect Schaaf et al., 2009 
Acetazolamide  
(used for raised 
intracranial pressure 
and metabolic 
alkylosis) 
Furosemide Diuretic effect augmented Libenson et.al., 1999 
Acetazolamide  Prednisone Development of hypokalemia Widmer et al., 1995 
Furosemide  Prednisone Development of hypokalemia Widmer et al., 1995 
Diazepam Phenobarbitone Additive CNS depressant effect Brockmeyer et al., 
1985 
Diazepam  Sodium 
Valproate 
Additive CNS depressant effect Dhillon  and Richens, 
1982 
Clonidine  
(used as part of sedation 
protocol) 
Diazepam Increased hypotensive effect  BNF, 2011 
Clonidine  Furosemide Increased hypotensive effect Williams et al., 2004 
Amikacin Furosemide Increased risk of ototoxicity Smith and Lietman, 
1983 
Aspirin Warfarin Increased risk of bleeding  Medical Research 
Council’s General 
Practice Research 
Framework, 1998 
Aspirin Enoxaparin Increased risk of bleeding  Kavanagh et al., 2004 
Furosemide Digoxin Increased cardiac toxicity risk Tsutsumi et al., 1979 
Spironolactone  Potassium 
chloride 
Increased risk of hyperkalemia Greenblatt and Koch-
Weser, 1973 
Furosemide Ibuprofen Increased risk of nephrotoxicity Huerta et al., 2005 
Ibuprofen Spironolactone Increased risk of hyperkalemia Hunt et al., 2009 
Captopril Spironolactone Increased risk of hyperkalemia Berry et al., 2001 
Gentamycin Benzyl 
penicillin 
Gentamycin inactivated by 
Benzyl penicillin 
SAMF, 2012 
*
BNF = British National Formulary  
**
SAMF = South African Medicines Formulary 
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Table 25, below, shows the potential pharmacokinetic (PK) drug-drug interactions 
(DDIs) of the sample  studied. 
 
 
 
 
 
Table 25: Potential pharmacokinetic (PK) drug-drug interactions (DDIs) 
Pharmacokinetic drug interactions 
 
Frequency of PK 
interactions 
95% CI 
No. of PK 
DDI’s 
% 
 
 Increase in distribution 15 1.2 0.6–1.9 
 Decrease in distribution 14  1.1 0.6–1.8 
 Decrease in metabolism   8  0.6       0.27–1.2 
 Decrease in absorption   7  0.6 0.2–1.1 
 Increase in metabolism   3  0.2 0.05–0.68 
 Increase in excretion   1  0.1       0.02–0.4 
 Decrease in excretion   1  0.1       0.02–0.4 
 Increase in absorption   0  0.0 0.0–0.0 
 
 Table 26, below, shows the potential PK drug-drug interactions (DDIs), not 
necessarily recorded by prescribers in the study but potentially present. 
 
Table 26: Description of potential PK drug interactions (DDIs) (as indicated in Table 25 
but not necessarily recorded by prescriber, however, potentially present) 
Drug A Drug B Potential pharmacokinetic interaction Reference(s) 
Omeprazole  Warfarin Elimination of warfarin prolonged by 
omeprazole, i.e., decrease in excretion of 
warfarin 
Garcia  et 
al., 1994 
Prednisone Isoniazid Prednisone reduces plasma concentration of 
Isoniazid, i.e., decrease in drug distribution 
Sarma  et al., 
1980 
Rifampicin  Prednisone Rifampicin accelerates metabolism of 
prednisone 
Buffington 
et al., 1976 
    
Sodium Valproate Phenobarbitone Valproate increases plasma concentration of 
phenobarbitone, i.e., increase in drug 
distribution 
Hurst  et al., 
1997;  
Bernus  et 
al., 1994 
Phenobarbitone Sodium Valproate Phenobarbitone reduces plasma concentration 
of phenobarbitone, i.e., decrease in drug 
distribution 
Hurst et al., 
1997; 
Bernus et al., 
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1994 
Ritonavir Prednisone Ritonavir increases plasma concentration of 
Prednisone, i.e., increase in drug distribution 
Busse et al.,  
2008 
Prednisone  Lopinavir/Ritonavir 
(Kaletra) 
Prednisone reduces Kaletra levels, i.e., 
decrease in drug distribution 
Busse et al., 
2008 
Lamivudine Trimethoprim Plasma concentration of Lamivudine 
increased by Trimethoprim, i.e., increase in 
drug distribution 
Sabo etal., 
2000 
Isoniazid  Paracetamol Isoniazid inhibits metabolism of paracetamol Chien et al., 
1997 
Prednisone  Isoniazid Prednisone reduces plasma concentration of 
Isoniazid, i.e., decrease in drug distribution 
Sarma et al., 
1980 
Isoniazid Prednisone Isoniazid metabolism increased by Prednisone Sarma et al., 
1980 
Co-trimoxazole Rifampicin Plasma levels of Co-trimoxazole reduced by 
Rifampicin, i.e., decrease in drug distribution 
Ribera et al., 
2001; 
Bhatia  et al., 
1991 
Omeprazole Diazepam Omeprazole inhibits the metabolism of 
diazepam 
Zomorodi& 
Houston, 
1996 
Phenobarbitone Clonazepam Phenobarbitone induces metabolism of 
clonazepam  
Khoo et al., 
1980 
Zinc Ciprofloxacin Zinc reduces absorption of Ciprofloxacin Polk, 1989 
Sodium Valproate Phenobarbitone Valproate increases plasma concentration of 
phenobarbitone, i.e., increase in drug 
distribution 
Hurst  et al., 
1997; 
Bernus et al., 
1994 
Phenobarbitone Sodium Valproate Phenobarbitone reduces plasma concentration 
of sodium valproate, i.e., decrease in drug 
distribution 
Hurst  et al., 
1997; 
Bernus et al., 
1994 
Phenobarbitone Neviripine NVP 
 
Phenobarbitone may decrease NVP levels, i.e., 
decrease in drug distribution 
L’homme  et 
al., 2006 
Co-trimoxazole Phenobarbitone Cotrimoxazole may inhibit Phenobarbitone 
metabolism 
SAMF, 2012 
Rifampicin Co-trimoxazole Rifampicin induces metabolism of Co-
trimoxazole 
Ribera et al., 
2001; Bhatia  
et al., 1991 
Trimethoprim 
(TMP) (as co-
trimoxazole) 
Lamivudine (3TC) TMP inhibits metabolism of 3TC  Sabo et al., 
2000 
Cimetidine Diazepam Cimetidine inhibits metabolism of diazepam  Lockniskar  
et al., 1986; 
Klotz  
&Reimann, 
1981 
 
 
 
 
84 
 
Ferrous Gluconate Thyroxine Absorption of thyroxine reduced by oral iron 
(ferrousgluconate) 
Campbell et 
al., 1992 
Zinc Ciprofloxacin Zinc reduces absorption of ciprofloxacin Polk et al., 
1989 
Morphine Ciprofloxacin Morphine induces metabolism of 
Ciprofloxacin  
Morran et 
al., 1989 
Cimetidine Carbamazepine Cimetidine decreases metabolism of 
Carbamezepine 
MacPhee et 
al., 1984 
Folate Phenobarbitone 
(PB) 
Folate induces metabolism of phenobarbitone, 
plasma concentration of PB reduced 
BNF, 2011 
Fluconazole Ritonavir Fluconazole inhibits metabolism of Ritonavir Peytavin et 
al., 2003 
Trimethoprim 
(TMP) (as co-
trimoxazole) 
Lamivudine (3TC) TMP increases plasma concentration of 3 TC, 
i.e., increase in drug distribution 
Sabo et al., 
2000 
Abacavir (ABC) Lamivudine (3TC) ABC decreases absorption of 3TC Wang et al., 
1999 
Fluconazole Zidovudine (AZT) Fluconazole increases plasma concentration of 
AZT. Increase in drug distribution 
Sahai et al., 
1994 
Sprironolactone Digoxin Spironolactone inhibits metabolism of digoxin Steimer, 
Muller 
&Eber, 2002 
Calcium 
compounds 
Zinc sulphate Absorption of Zinc sulphate reduced by 
Calcium compounds 
Argiratos  et 
al., 1994 
Phenobarbitone Neviripine NVP 
 
Phenobarbitone decreases NVP levels, i.e., 
decrease in drug distribution 
L’homme  et 
al., 2006 
Phenobarbitone Sodium Valproate Phenobarbitone reduces plasma concentration 
of sodium valproate, i.e., decrease in drug 
distribution 
Hurst et al., 
1997; 
Bernus et al., 
1994 
Sodium Valproate Phenobarbitone Valproate increases plasma concentration of 
phenobarbitone, i.e., increase in drug 
distribution. 
Hurst  et al., 
1997; 
Bernus et al., 
1994 
Co-trimoxazole Rifampicin Plasma levels of Co-trimoxazole reduced by 
Rifampicin, i.e., decrease in drug distribution 
Ribera et al., 
2001; Bhatia 
et al., 1991 
Prednisone  Isoniazid Prednisone reduces plasma concentration of 
Isoniazid, i.e., decrease in drug distribution 
Sarma et al., 
1980 
Lamivudine Trimethoprim (as 
Co-trimoxazole) 
Plasma concentration of Lamivudine 
increased by Trimethoprim, i.e., increase in 
drug distribution 
Sabo et al., 
2000 
Sodium Valproate Phenobarbitone Valproate increases plasma concentration of 
phenobarbitone, i.e., increase in drug 
distribution. 
Hurst et al., 
1997; 
Bernus et al., 
1994 
Co-trimoxazole Rifampicin Plasma levels of Co-trimoxazole reduced by Ribera et al., 
 
 
 
 
85 
 
Rifampicin, i.e., decrease in drug distribution 2001; Bhatia 
et al., 1991 
Prednisone  Isoniazid Prednisone reduces plasma concentration of 
Isoniazid, i.e., decrease in drug distribution 
Sarma et al., 
1980 
Sodium Valproate Phenobarbitone Valproate increases plasma concentration of 
phenobarbitone, i.e., increase in drug 
distribution 
Hurst et al., 
1997;  
Bernus et al., 
1994 
Lamivudine Trimethoprim (as 
Co-trimoxazole) 
Plasma concentration of Lamivudine 
increased by Trimethoprim, i.e., increase in 
drug distribution 
Sabo et al., 
2000 
Trimethoprim 
(TMP) ( as co-
trimoxazole) 
Lamivudine (3TC) TMP increases plasma concentration of 3 TC, 
i.e., increase in drug distribution 
Sabo et al., 
2000 
Ritonavir Prednisone Ritonavir increases plasma concentration of 
Prednisone, i.e., increase in drug distribution 
Busse et al., 
2008 
Sodium Valproate Phenobarbitone Valproate increases plasma concentration of 
phenobarbitone, i.e., increase in drug 
distribution 
Hurst et al., 
1997;  
Bernus et al., 
1994 
Ritonavir Prednisone Ritonavir increases plasma concentration of 
Prednisone 
Busse et al., 
2008 
Ritonavir Prednisone Ritonavir increases plasma concentration of 
Prednisone, i.e., increase in drug distribution 
Busse et al., 
2008 
*
SAMF = South African Medicines Formulary  
**
BNF = British National Formulary 
 
4.5 Drug-disease interactions  
Potential drug-disease interactions  (DDiS) were potentially present in the study sample, but 
not necessarily recorded by the prescriber. Table 27, following, shows potential DDiS. 
 
Table 27: Potential drug-disease interactions ( new terminology, to be added)(DDiS) 
 
Drug-induced diseases (DDiS) 
 
   
95%CI No. (%) 
Hepatotoxicity 16 1.3 0.7–2.0 
Nephrotoxicity   9 0.7 0.3–1.3 
Other   7 0.6 0.22–1.12 
Blood disorders   4 0.3 0.09–0.80 
Change in glucose levels   2 0.2 0.02–0.60 
Ototoxicity   1 0.1 0.02–0.43 
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Table 28, below, provides a description of potential DDiS tabulated earlier. 
Table 28: Description of the potential DDiS as indicated in Table 27 
Drug Disease Potential DdiS Reference(s) 
Aspirin Sepsis* Symptoms of infection 
(sepsis) may be masked by 
aspirin 
Habib et al., 2013; 
Amann&Peskar, 2002 
Isoniazid Drug-induced hepatitis 
(causative agent =  Azathioprine) 
potential exacerbation of 
hepatotoxicity, patient 
already has high liver 
enzymes and drug-induced 
hepatitis 
Possuelo et al., 2008 
Paracetamol Drug-induced hepatitis 
(causative agent =  Azathioprine) 
 potential exacerbation of 
hepatotoxicity, patient 
already has high liver 
enzymes and drug-induced 
hepatitis 
Rivera-Penera et al., 
1997 
Chloroquine Drug-induced hepatitis (causative 
agent = Azathioprine) 
potential exacerbation of 
hepatotoxicity, patient 
already has high liver 
enzymes and drug-induced 
hepatitis 
Mottaghi&Karimzade, 
2005 
Chloroquine Systemic Lupus Erythromatosus 
(SLE) 
Increased risk of blood 
disorders, patient has SLE 
Ruiz-Irastorza et al., 
2010 
Cotrimoxazole HaemophagocyticLymphohistiocytosis 
(HLH) and Hepatic Impairment (HI) 
Cotrimoxazole increases 
induction of liver enzymes 
and to be used cautiously in 
serious haematological 
disorders  
Ransohoff and Jacobs , 
1981; Abi Mansur et 
al., 1981; Yao et al., 
1997; Altraif et al., 
1994 
    
Clonazepam Hepatic Encaphalopathy (HE) Clonazepam is 
contraindicated in HE 
Mullen et al., 1996 
Phenobarbitone 
 
Hepatic Encaphalopathy (HE) Phenobarbitone is 
contraindicated in HE 
Aiges et al., 1980 
Co-trimoxazole Haematological Disorder (HD) 
(anaemia) 
Cotrimoxazole to be used 
cautiously in anaemia patient 
Yao et al., 1997 
Co-trimoxazole Hepatic Impairment (HI) (increase in 
liver enzymes) 
Cotrimoxazole to be used 
cautiously in patient with HI 
Ransohoff&Jacobs, 
1981; Abi Mansur et 
al., 1981; Yao et al., 
1997; Altraif et al., 
1994 
Phenobarbitone Hepatic Impairment (HI ) Phenobarbitone use is 
contraindicated in patient 
with HI 
Aiges et al., 1980 
Dexamethasone Chronic Gastro-enterirtis* (CGE) Exacerbation of gastro-
intestinal tract (g.i.t) 
symptoms ( diarrhoea ) 
SAMF, 2012 
Cotrimoxazole Chronic Gastro-enterirtis*(CGE) Exacerbation of g.i.t Sheikh et al., 2009 
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symptoms 
(diarrhoea) 
Ethambutol Acute renal failure (ARF) Ethambutol to be used 
cautiously in patients with 
ARF 
Garcia-Martin et al., 
1996 
Pyrazinamide Acute renal failure (ARF) Pyrazinamide to be used 
cautiously in patients with 
ARF 
Sanwikarja et al., 1999 
Acetazolamide Acute renal failure (ARF) Acetazolamide is contra-
indicated in renal impairment  
Higgenbottom, Ogg& 
Saxton, 1978 
Diazepam Acute renal failure (ARF) Diazepam is cautioned in 
renal impairment 
SAMF, 2012 
Co-trimoxazole Acute renal failure (ARF) Co-trimoxazole is contra-
indicated in renal impairment 
Windecker et al., 2000; 
Kraemer et al., 1982 
Fluconazole Renal impairment Fluconazole is contra-
indicated in renal impairment 
SAMF, 2012 
Co-trimoxazole Haematological disorders (HD) Co-trimoxazole to be used 
cautiously in HD 
Heimpel&Raghavachar, 
1987 
Paracetamol Haematological disorders (HD) Paracetamol to be used 
cautiously in HD 
Aster et al., 2009 
Amoxycillin Chronic gastro-enteritis (CGE) Amoxycillin can exacerbate 
CGE 
Elliot, 2007 
Cimetidine Refractory seizures* Cimetidine can exacerbate 
seizures (side effects of 
Cimetidine includes seizures) 
Macphee et al., 1984 
Acyclovir Chronic Gastro-enterirtis* (CGE) Acyclovir may aggravate 
diarrhoea 
SAMF, 2012 
Ertepenem Renal impairment Ertepenem may aggravate 
renal impairment 
SAMF, 2012 
Oseltamivir Conjunctivitis* Conjunctivitis is a side effect 
of Oseltamivir and patient 
already has conjunctivitis 
SAMF, 2012 
Paracetamol Haemolytic Anaemia Side effects of Paracetamol 
includes thrombocytopenia 
and neutropenia. Paracetamol 
use can further aggravate the 
condition 
 Aster et al., 2009 
Omeprazole Haemolytic Anaemia Side effects of Omeprazole 
includes pancytopenia, 
thrombocytopenia, 
leucopenia, agranulocytosis, 
and haemolytic anaemia. 
Omeprazole can aggravate 
the condition 
Landray et.al, 1998 
 
Cimetidine Pancreatitis* Cimetidine exacerbates 
pancreatitis 
Eland et.al, 2000; 
Nott and De Sousa , 
1989 
Cimetidine Renal impairment Cimetidine to be used 
cautiously in renal patients 
Rudnick et al., 1982 
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Ertepenem Renal impairment Ertepenem may aggravate 
renal impairment 
SAMF, 2012 
Cotrimoxazole Hepatic Impairment (HI) (increase in 
liver enzymes) 
Cotrimoxazole to be used 
cautiously in patient with HI 
Ransohoff&Jacobs, 
1981; Abi Mansur et 
al., 1981; Yao et al., 
1997, Altraif et al., 
1994  
Phenobarbitone Hepatic Impairment (HI) Phenobarbitone use is 
contraindicated in patient 
with HI 
Aiges et al., 1980 
Paracetamol Haematological Disorders (HD) Paracetamol to be used 
cautiously in HD 
Aster et al., 2009 
Diazepam  Hepatic Encephalopathy (HE) Diazepam is contraindicated 
in HE 
Hermann et al., 1983 
Clonazepam Drug induced Hepatic Encephalopathy 
(HE) 
Diazepam is contraindicated 
in HE 
Mullen et al., 1996 
Omeprazole Jaundice Omeprazole can aggravate 
jaundice 
Jochem et al., 1992 
Paracetamol Increased liver enzymes Paracetamol to be used 
cautiously in patient with 
raised liver enzymes 
Rivera-Penera  et al., 
1997 
Prednisone Hyperglycemia Prednisone can further 
increase glucose levels 
Ferris & Kahn , 2012 
Gentamycin Hearing loss Gentamycin can cause 
ototoxicity 
SAMF, 2012 
Prednisone Hyperglycemia Prednisone can further 
increase glucose levels 
Ferris & Kahn, 2012 
*other DDiS 
4.6 Off–label prescribing 
 A relatively higher number of OL prescribing with regards to age of patients was observed, 
as may be observed in Table 29, below, which also indicates other, formulation, route, and 
dose errors in OL prescriptions. 
 
Table 29: Off-label prescribing 
Type of OL prescribing No.  % 95% CI 
Age 24 1.9    1.2–2.8 
Other (a drug prescribed for a condition for 
which it was not approved) 
16 1.3 0.72–2.0 
Formulation  8 0.6   0.3–1.2 
Route   5 0.3   0.13–0.90 
Dose  4 0.3   0.09–0.80 
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Table 30, following, provides a description of OL prescribing in the study sample, as 
indicated earlier in Table 28. 
 
Table 30: Description of Off-label (OL) prescribing as indicated in Table 29 
 
Type of OL  
(in terms of age, formulation, 
route, dose, and other) 
Drug Description of OL 
Age Ethambutol Ethambutol not recommended for 
children aged under 8 years 
Other 
 (Chloroquine prescribed for a 
condition completely different from 
those for which the drug was 
approved) 
Chloroquine Chloroquine prescribed for Idiopathic 
Pulmonary Hemosiderosis (IPH) 
Other 
 (Clonidine prescribed for a 
condition completely different from 
those for which the drug was 
approved) 
Clonidine Clonidine prescribed as part of 
sedation protocol 
Route Gentamycin Parenteral Gentamycin prescribed as 
oral, as part of bowel “cocktail” 
Other 
(Clonidine prescribed for a condition 
completely different from those for 
which the drug was approved) 
Cholestyramine Cholestyramine, a bile acid 
sequestrant, prescribed as part of bowel 
“cocktail” 
Age  Cholestyramine Not recommended for children aged 
under 2 years. Patient is one month old 
Formulation Omeprazole Omeprazole oral tablet changed to oral 
solution 
Age Oseltamivir Not registered for children aged under 
1 year 
Other 
 (Clonidine prescribed for a 
condition completely different from 
those for which the drug was 
approved) 
Gabapentin 
 
Used for neuropathic pain 
Other 
 (Amitriptylline prescribed for a 
condition completely different from 
those for which the drug was 
approved) 
Amitriptyline Used as an adjuvant to pain relief in 
chronic pain syndrome 
Other 
 (Clonidine prescribed for a 
condition completely different from 
those for which the drug was 
Clonidine Clonidine prescribed as part of 
sedation protocol 
 
 
 
 
90 
 
approved) 
Dose Clonidine Paediatric dose not established for 
children aged under 12 years 
Age Omeprazole Omeprazole registered for short term 
use (3 months) for GORD in children 
aged older than 1 year 
Formulation Omeprazole Omeprazole tablet formulated into 
solution formulation 
Route Omeprazole Oral formulation prescribed as via 
naso-gastric tube (NGT) 
Route Co-trimoxazole  Oral formulation prescribed as via 
NGT 
Route Prednisone Oral formulation prescribed as via 
NGT 
Age Omeprazole Not registered for children aged under 
1 year 
Formulation Omeprazole Omeprazole tablet formulated into 
solution formulation 
Age Montelukast Safety and efficacy not established in 
children aged under 2 years 
Age Tilidine HCl Tilidine HCl should not be prescribed 
and administered in infants aged under 
1 year 
Other 
 (Mesna prescribed for a condition 
completely different from that for 
which the drug was approved) 
Mesna Mesna, a purine analogue usually 
prescribed as an inhalation, to reduce 
sputum to prevent urothelial toxicity 
Other 
(Clonidine prescribed for a condition 
completely different from those for 
which the drug was approved) 
Clonidine Clonidine prescribed as part of 
sedation protocol 
Dose Clonidine Paediatric dose not established for 
children aged under 12 years 
Dose Clonidine Paediatric dose not established for 
children aged under 12 years 
Age Ciprofloxacin Not licensed for use in neonates 
Other 
 (Gabapentin prescribed for a 
condition completely different from 
that for which the drug was 
approved) 
Gabapentin Prescribed for neuropathic pain 
(unregistered indication) 
Other (Unregistered in South Africa) Phenobarbitone IV Phenobarbitone IV unregistered 
Dose Clonidine Paediatric dose not established for 
children aged under 12 years 
Age Oseltamivir Not recommended for children aged 
under 1 year 
Age Prostaglandin Not recommended in children 
Other 
 (Prostaglandin prescribed for a 
Prostaglandin Prescribed as part of Pulmonary 
Hypertension regimen 
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condition completely different from 
that for which the drug was 
approved) 
Other 
 (Clonidine prescribed for a 
condition completely different from 
that for which the drug was 
approved) 
Clonidine Prescribed as part of sedation protocol 
Age Clonidine Not registered for use in children aged 
under 12 years 
Age  Gabapentin Not registered for use in children aged 
under 12 years 
Other 
 (Gabapentin prescribed for a 
condition completely different from 
that for which the drug was 
approved) 
Gabapentin Prescribed for neuropathic pain  
(unregistered indication ) 
Age Meropenem Not recommended for children aged 
under 1 month 
Age Cholestyramine Use not recommended for children 
aged under 2 years 
Formulation Gentamycin Parenteral formulation prescribed as 
oral dose as part of bowel “cocktail” 
Age  Cholestyramine Not indicated for children aged under 2 
years 
Age Oseltamivir Not for use in children aged less than 1 
year 
Age Ethambutol Ethambutol not recommended for 
children aged under 8 years 
Age Meropenem Not recommended for children aged 
under 1 month 
Age Cholestyramine Use not recommended for children 
aged under 2 years 
Age Clonidine Not registered for use in children aged 
under 12 years 
Age  Gabapentin Not registered for use in children aged 
under 12 years 
Age Oseltamivir Not recommended for children aged 
under 1 year 
Age Prostaglandin Not recommended in children 
Other 
(Gabapentin prescribed for a 
condition completely different from 
that for which the drug was 
approved) 
Gabapentin Prescribed for neuropathic pain 
(unregistered indication ) 
Formulation Omeprazole Omeprazole tablet formulated into 
solution 
Formulation Gentamycin Parenteral formulation prescribed as 
oral dose as part of bowel “cocktail” 
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Formulation Omeprazole Omeprazole tablet formulated into 
solution 
Route Omeprazole Oral formulation prescribed as via 
naso-gastric tube (NGT) 
 
4.7 Determinants of or risk factors for prescribing errors 
To identify risk factors associated with prescription errors, the following variables were 
examined: doctor category, class of drug, ward location, drug formulation, formulary, patient 
age category, day of the week when drug items were prescribed, and the number of drug 
items prescribed per prescription chart.  
Table 31, following, shows the risk factors or determinants associated with a 
prescribing error. The determinants of the risk factors of prescribing errors were not 
necessarily mutually exclusive and the determinants reflected factors involved in the 
prescribing practice in a teaching hospital, for example, the RCWMCH, where the study was 
conducted.  
It can be said that junior prescribers, to some extent, mimic their senior counterparts; 
thus, the recurring type of prescribing errors frequently observed during the current study, 
namely, missing information. Secondly, the senior doctors who were more involved than 
their junior counterparts in prescribing in the specialty wards were more prone to make 
mistakes in these wards.  
The only other interesting determinant of risk factor, relatively easy to observe, was 
occurrence of more errors during the busier times in the hospital, that is, during weekdays. 
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Table 31: Risk factors associated with ANY prescribing error 
Factor 
Total 
N 
1 282 
Any 
error 
n 
% 
Any error 
 
Univariate analysis 
Multivariate analysis 
OR 
95% CI 
p value OR  
95% CI 
P 
value 
Level of experience 
Junior 405 242 59.75 Referent — Referent — 
Senior 877 687 78.34 2.435 
(1.886–3.144) 
<0.001 1.954 
(1.463–2.608) 
<0.0
01 
Class of drug 
Antibiotics 271 206 76.01 Referent — Referent — 
Vitamins 
and 
minerals 
438 305 69.63 0.724 
(0.512–1.022) 
0.066 — — 
Other 573 418 72.95 0.851 
(0.609–1.189) 
0.344 — — 
Ward location 
Specialty 426 349 81.92 Referent — Referent — 
General 856 580 67.76 0.463 
(0.349–0.617) 
<0.001 0.653 
(0.473–0.901) 
0.010 
Formulation 
Oral 991 717 72.35 Referent — Referent — 
Other 291 212 72.85 1.026 
(0.765–1.375) 
0.866 — — 
Formulary 
Yes 1282 929 72.5 Referent — Referent — 
No 0 0 0* Cannot be 
estimated 
Cannot be 
estimated 
— — 
Age of patient (in months (mo)) 
0–12 
months 
506 367 72.53 Referent — Referent 
(0–12 months 
combined with 
> 60 months) 
— 
13–60 
months 
404 278 68.81 0.835 
(0.627–1.114) 
0.220 0.767 
(0.587–1.001) 
0.051 
>60 months 372 284 76.34 1.222 
(0.898–1.664) 
0.202 Referent 
(see above) 
— 
Day 
Weekday 1 017 752 73.9 Referent — 
 
Referent — 
Weekend 260 172 66.1 0.671 
(0.503–0.895) 
0.007 0.710 
(0.527–0.955) 
0.024 
Missing 
dates on 
prescription 
(no day 
5 5 100 — — — — 
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could be 
allocated 
for five 
prescribed 
drug items) 
No. of drugs items prescribed 
1–5 drug 
items 
89 59 66.29 Referent — Referent — 
>5 drug 
items 
111 84 75.68 1.582 
(0.853–2.933) 
0.145 — — 
 
Univariate and multivariate logistic regression was used to identify risk factors 
associated with a prescribing error. The odds ratio (OR) indicates the odds of the category 
making an error compared to that of the referent category. For the multivariate analysis, no 
prior information was given. There were no adjustments or controls. All variables with a p-
value less than 0.25 in the univariate analysis were considered. The model was run and 
insignificant variables removed. Attention was also given to changes in the model. No major 
changes were noted. 
The final model showed senior doctors (registrars and consultants) to be almost twice 
as likely to make a mistake, compared to the juniors (interns and SHO’s). Prescriptions 
written up in the general medical wards (B1 and B2) had less errors compared to those 
written up in the specialty wards (that is, PICU and G1). Prescribing errors were generally, 
less likely to occur over weekends compared to weekdays. These were the only significant 
variables found in the study sample.Although children aged 13 to 60 months experienced a 
reduced error risk, this did not quite reach statistical significance. 
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Chapter 5 
Discussion  
Key points based on the outcomes of the study objectives, will be discussed in this chapter. 
The findings of the study at RCWMCH will be compared to the findings of the literature 
reviewed.Patient characteristics in terms of age and nutritional status of the patient and the 
drug treatment regimen prescribed for them, will be briefly included The types of prescribing 
errors encountered in the study, the potential drug-drug interactions (DDIs), drug-disease 
interactions (DDiS), and off-label (OL) prescribing will be discussed. In addition important 
observations for each of these within the context of the study objectives will be mentioned. 
Determinants of prescribing errors will be discussed, based on the results as observed in the 
study. Limitations of the study conducted, will be mentioned in terms of prescription chart 
used, the reporting (or under-reporting) of drug interactions, drug-disease interactions and 
off-label prescribing and lack of investigators. 
The main objectives of the study were as follows: (1) to describe the types of 
prescribing errors and error frequency, (2) to describe the prescribing error frequency per 
different classes of drugs, (3) to identify potential drug interactions (DDIs), (4) to identify 
potential drug-disease interactions (DDiS, (5) to describe off-label (OL) prescribing, and 6) to 
identify risks or determinants for prescribing errors. The study was conducted in two medical 
wards and two speciality wards, prescribing practice of doctors from different specialities and 
from different levels of experience considered for the purpose of searching for the objectives 
listed. The methodological features of this study design accurately described the prescribing 
practice, also allowing for critical appraisal and analysis of the prescribing practice. The 
statistical analysis of the data allowed for identification of the related risk factors associated 
with prescribing errors. 
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5.1 Patients characteristics 
In the sample in the present study, 104 patients were aged below 24 months (52%), compared 
to a 255 study sample ( included both adults and children) in which 52% were children, in a 
study conducted by Grimwood and his colleagues, focusing on antimicrobial prescribing 
errors, with age(s) ranging from 0.2 months to 144 months (Grimwood,Cook & Abbott, 
1983). In the)study at RCWMCH, 65% of the patients in the sample were either moderate or 
severely underweight, compared to 41.2% underweight children aged between 60 to 180 
months in a study carried out in India (Srivasta et al., 2012). Only  15.5% of the patients in 
the study sample were HIV-infected, compared to the 100% HIV infection rate among 
patients in a retrospective study conducted by Norah in South Africa (Norah, 2011). 
Treatment protocols for children who were underweight for age, included zinc, folate, 
and multivitamins. This reflects adherence at the RCWMCH to the 10 steps recommended by 
WHO (World Health Organisation, 1999) in the treatment of malnutrition. Where necessary 
and as the need arose, elemental iron and other trace elements were prescribed.Vitamin A 
were also administered to the children and they were de-wormed when indicated, a practice 
often done in the short stay ward. These drugs were  not  always included in the “real time” 
study review of the prescription charts since they had already been prescribed and 
administered as stat (at once) doses .Nutritional medicines ( zinc,folate & multivitamins) 
were prescribed before arrival to the ward ( in some cases only).  In a few cases it was  
prescribed as stat doses in short stay ward ( excluded in study),   in most cases the   
nutritional medicines were prescribed within the respective wards.  
 Antibiotics and other disease-specific treatments were prescribed on an individual 
basis.  A similar study in India in 2011on 41.2% underweight children also showed anaemia 
as the most common condition in the underweight group (Srivasta et al., 2012); as for the 
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underweight group in the study at RCWMCH, drug treatment regimen included drugs such as 
zinc, folate, and vitamins. Although vitamin A disorders amongst the underweight group was 
not very common (3.4% of the sample) in the India study, the children were still treated with 
it where it was deemed necessary. 
5.2 Prescribing errors 
 The study showed that prescribing practice in terms of prescribing errors was easily 
identifiable seeing there were no significant differences in the types of prescribing errors 
made by senior and junior doctors. There was, however, a significant difference in the 
frequency of prescribing errors made by senior and junior doctors, that is, senior doctors 
made more prescribing errors than did junior doctors. 
 A total of 929 prescribing errors (72.5%) was found in the study, with incomplete 
information (65.6%) observed as the most common type of error. In comparison to a study in 
Wales over a period of 24 months with a sample size of 682 patients (Wilson et.al, 1998), 
prescribing errors accounted for 68%, of which incomplete information (36%) presented as 
amongst the most common type of errors. 
 Incomplete information, the leading type of prescribing error by far (see Table 15 in 
Chapter 4 of this thesis on page 77, shows that prescribers were not following prescribing 
STGs (guidelines) stipulated in the Medicines and related substances Act 101, 1965 
(Medicines and Related Substance Act 101 of 1965, Regulations as amended, 2014: 28) as 
well as those provided by the RCWMCH. A possible prescribing practice that could have 
contributed to this situation is the format of the prescription chart used in wards B1, B2, and 
G1, which was different to the one used in the PICU ward (see Appendix  C and D ) for 
format of the prescription charts), that is, in effect, no standardisation of prescription charts 
used at the hospital. Even though only 12.8% (164 of a total of 1 282 in the overall sample) 
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accounted for drug items prescribed for infants, 155 of the 164 drugs prescribed had one or 
more prescribing errors (94%), that is, most of the prescribing errors occurred in this age 
category. 
The nature of the prescribing errors is seen to have centred on the writing style of the 
prescriber, incomplete information, wrong drug names, and use of abbreviations; all of these 
featured as the most prominent types of prescribing errors. Prescribing errors due to the 
decision-making of the prescriber were low and included alteration of a dose and or 
frequency, dose too high, and dose too low. For other type of errors (such as inappropriate 
drug, unnecessary drug therapy, and unauthorised prescriber), the occurrence was low. 
 There were 929 prescribing errors out of a total of 1 282 drugs prescribed (72.5%) in 
the study sample, with 200 prescriptions reviewed in all. In a retrospective study carried out 
by Kozer et al. (2002) in the ED of a hospital in Canada, it was found that trainees (junior 
doctors) were most likely to make prescribing errors; however, in contrast, in the study based 
at the RCWMCH, it was found that the registrars (senior doctors) were responsible for most 
of the recorded prescribing errors. The registrars took most of the responsibility for initiating 
and completing prescription charts, thus increasing the chances for prescribing errors being 
made. 
If one compares, for example, one of the main concerns relating to prescribing errors, 
that is, incomplete prescription (or missing information), then the study done at the 
University Hospital in Wales (Wilson, 1998), showed that incomplete information was 
among the highest types of prescribing errors. Similarly, as mentioned earlier, for the study at 
the RCWMCH, incomplete prescription (missing information) was the most recurring type of 
prescribing error, followed by use of wrong name for the prescribed drug and use of 
abbreviations.  
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The error frequency for drugs by different classes of drugs was high for most of the 
categories. The study at RCWMCH, compared with some of the findings in similar studies 
done previously, showed that a rational approach to instil good prescribing should be 
planned, implemented, and monitored. In this regard, for example, in a study undertaken at a 
tertiary teaching hospital in New York from 1 July 1994 to 30 June 1995 (Lesar, 1997), as 
with the study at RCWMCH, results showed antimicrobials to be one of the classes of drugs 
most commonly involved in prescribing errors. In the study, antibiotics was the second class 
of drugs most commonly prescribed, at times irrationally, during clinical intervention and 
when an unauthorised prescriber (effectively, this being another type of prescribing error) 
prescribed restricted antibiotics. The irrational prescribing of antibiotics has the potential to 
increase resistance in a patient; thus intervention through antibiotic stewardship that includes 
a pharmacist as part of the prescribing team during ward rounds, will improve future practice 
of this very significant class of drugs at the RCWMCH. 
Most drugs were prescribed in the general medical wards, as observed in the results of 
the study presented in Chapter 4 (Table 9 on page 72) of this thesis. Interestingly, ward G1, a 
speciality ward, had a higher error rate (1.43) compared to the PICU ward (also a specialty 
ward) and the two general medical wards involved in the study. Similarly, in a study 
conducted at a tertiary care teaching hospital in New York from 1 July 2000 to 4 January 
2002 medication errors were observed in the neonatal, PICU, and general paediatric wards 
(Lesar, 2002). It was observed that tenfold prescribing errors occurred in the 
paediatric/neonatal ICU (Lesar, 2002).  In G1, the oncology ward, important information 
missing from the prescription chart, contributed towards the high  prescribing error rate. 
Another similarity between the study and another carried out by Kozer and colleagues in 
2000 in Canada related to weekdays versus weekends for occurrence rate of prescribing 
errors; in both studies there was an increased risk of prescribing errors occurring during 
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weekdays, an indication that the volume of prescriptions generated during weekdays is 
greater than that over weekends. The univariate analysis of the study carried out by Kozer et 
al. (2000) also revealed that it is the younger age group that was associated with a greater 
number of prescribing errors compared to older children. Similarly, in the study, the younger 
age group was at greater risk for prescribing errors. A wrong prescribed dose, based on small 
body weight and surface area, also resulted in more prescribing errors in the younger age 
group (1.03–12 months), as observed in the results presented in Chapter 4 (Table 20 on page 
82 of this study).  
 
 
5.3 Potential drug interactions  
 Potential drug interactions (DDIs) were minimal, indicating that the doctor might have 
considered the possibility of a potential interaction, prescribing sensibly, that is, only in the 
event that of the drug interactions being beneficial. Potential pharmacodynamic drug 
interactions were more likely to occur than pharmacokinetic drug interactions, even though 
not necessarily reported in the clinical notes of the patient. Pharmacodynamic interactions 
were generally more intuitive for those with advanced medical training (as observed in the 
PICU ward) because the interacting drugs had related actions. An example of the synergistic 
effect of two drugs prescribed as per PICU sedation protocol is illustrated by the potential 
interaction between diazepam (CNS depressant) and morphine (opioid analgesic). This 
potential drug interaction led to pronounced CNS depression, which was a desired outcome 
as observed in this study.  
Another example in the current study of a pharmacodynamic interaction was that 
between acetazolamide (a carbonic anhydrase inhibitor) used for raised intracranial pressure 
and furosemide (a loop diuretic). The diuretic effect was augmented, by increased sodium 
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load delivered to the collecting duct. In addition acetazolamide increased potassium 
excretion, resulting in hypokalemia, as indicated in the laboratory results (Libenson et.al., 
1999). Another example of a pharmacodynamic interaction, observed in my study, was in a 
renally compromised patient, who received both furosemide (a loop diuretic) and ibuprofen 
(a non-steroidal anti-inflammatory drug (NSAID). Renal impairment, as observed in the 
clinical notes, worsened in this particular case. Ibuprofen can cause renal impairment, 
particularly in patients with hypovolaemia or dehydration and in whom prostaglandins are 
playing an important role in maintaining renal function. Hence, the concurrent use of 
furosemide and ibuprofen may increase the nephrotoxicity of NSAIDs . Additive central 
nervous system (CNS) was observed in two cases; in the first case, the patient received both 
diazepam (a benzodiazepine) and phenobarbitone. A simple synergistic effect (Brockmeyer 
et.al., 1985) was observed, as desired by the prescriber. Similarly, in the second case, the 
patient received both diazepam and sodium valproate. The latter drug has the potential to 
slightly increase the sedative effect of the former drug (Dhillon&Richens, 1982), a desired 
outcome, as observed. 
An observed daily decrease in the blood was recorded on the vital signs recording 
chart, indicated a potential hypotensive effect, possibly caused by interacting drugs. Drug 
interactions between furosemide and captopril showed potential additive hypotensive effect. 
Laboratory results, as recorded in the clinical notes of the patient, also helped in identifying 
potential drug interactions. For example, the potential interaction between captopril and 
spironolactone, observed in two cases in my study, led to a potential increase in potassium 
levels. Captopril (an ACE inhibitor) reduces plasma levels of aldosterone, which results in 
the retention of potassium. This would be expected to be additive, with the potassium 
retaining effects of spironolactone leading to hyperkalaemia (Berry et.al., 2001). Another 
important potential pharmacodynamic interaction observed in the present study was that 
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between aspirin and warfarin. A higher than normal international normalised ratio (INR) 
value, observed in the clinical notes, was indicative of a high warfarin dose. Increased risk of 
bleeding may occur even in a low dose of aspirin (75mg) when prescribed concurrently with 
warfarin. In addition, aspirin has a direct irritant effect on the stomach lining and can cause 
gastrointestinal bleeding; it also decreases platelet aggregation and prolongs bleeding time 
(Weil et.al, 1995). 
 In the study, pharmacokinetic drug interaction between ethambutol and 
pyrazinamide, that is, an additive potential for elevation of serum urate or clinically 
significant, hyperuricaemia Both drugs were prescribed in the intensive and continuation 
phase of TB). Another pharmacokinetic drug interaction of note was that between sodium 
valproate and phenobarbitone, both anti-epileptic drugs, readily prescribed for patients with 
uncontrolled seizures. In eight cases of pharmacokinetic drug interactions observed during 
the present study, phenobarbitone plasma concentrations levels were raised. Valproate has the 
potential of increasing the plasma concentration of phenobarbitone, that is, increases drug 
distribution (Hurst, 1997). Conversely, plasma concentration of valproate was reduced by 
phenobarbitone in most cases, as indicated by the laboratory results. In a study undertaken at 
a teaching hospital in Brazil by Martinbiancho et al. (2007) in 2006, similar potential drug 
interactions were identified. Examples included the concurrent use of valproic acid and 
phenobarbitone, increased serum levels of phenobarbitone, and reduced effects of valproic 
acid. There was a difference in identifying and notifying  these potential drug-drug 
interactions. In the study undertaken at RCWMCH, the pharmacist was solely responsible for 
identifying the potential interaction and notifying the prescriber during ward rounds, whereas 
in the study by Martinbiancho et al. (2007) from January 2005 and December 2006,  the 
utilisation of computer programs was the most effective way of identifying potential drug 
interactions and notifying prescribers. 
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 Two other potential pharmacokinetic drug interactions, that were clinically 
significant, were those between cimetidine (H2-receptor antagonist) and diazepam (a 
benzodiazepine) and between omeprazole (a proton pump inhibitor) and diazepam. Both 
cimetidine and omeprazole have the potential to inhibit the metabolism of diazepam, thus 
delaying the elimination of diazepam and leading to increased or prolonged effect 
(Lockniskar&Zomorodi, 1996). Zinc was commonly prescribed as a supplement in patients 
with nutritional concerns and a potential drug interaction with ciprofloxacin (a quinolone 
antibiotic) was observed. Both drugs were prescribed for being given at the same time, zinc 
once daily (at 08h00) and ciprofloxacin twice daily (at 8h00 and 20h00). Since zinc has the 
potential to reduce the absorption of ciprofloxacin (Polk, 1989), therapeutic outcome was 
compromised in one patient, though not necessarily reported. Advice was given to administer 
the two drugs two hours apart. The potential for drugs to interact is real, even though the 
actual outcome may be difficult to measure. The prescriber should exercise caution to 
minimise additive harmful effects due to an overlooked drug interaction. 
 
5.4 Drug-disease interactions 
The potential for a drug-disease interactions was very low, thus no adverse event was 
observed during the period in which the study was undertaken. The potential to exacerbate a 
pre-existing liver disease was relatively more common than other types of potential drug-
disease interactions. 
In two separate cases where both patients were diagnosed with hepatic 
encephalopathy, diazepam was prescribed in the one case and clonazepam in the other, even 
though both drugs are contra-indicated for patients with hepatic encephalopathy (Mullen et 
al., 1996). The laboratory reports of both showed increased levels of liver enzymes. In two 
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other cases, both patients were diagnosed with hyperglycemia, with prednisone prescribed as 
part of a treatment regimen for TB. Prednisone increased the glucose levels in both patients. 
Documented evidence by Ferris (2012) shows that prednisone has the potential to increase 
glucose levels by inhibiting a number of steps in the insulin signalling network. Thus, the 
disease state of the patient should be carefully considered before potentially harmful drugs 
are prescribed to compromised patients. 
5.5 Adverse Drug Reactions: 
Adverse drug reactions (ADR’s) are not intended and occur at normal doses of medicines. 
The identification of ADR’s is dependant upon health professionals being alert and reporting 
any such event. It can be difficult to identify a true ADR and it rests with the all healthcare 
professionals to suspect for the occurrence of an ADR, particularly in infants and children.In 
one particular case in the study, the patient was diagnosed with drug induced hepatitis,a 
known adverse drug reaction of azathioprine. Isoniazid was given prophylactically to the 
same patient, the latter which caused an increase in liver enzymes, that is, an increased risk of 
drug interaction leading to the worsening of hepatotoxicity (Possuelo et al., 2008). This 
patient was also prescribed paracetamol, thus further increasing the risk of hepatotoxicity 
(Rivera-Penera et al., 1997).The patient was also prescribed chloroquine, compounding  the 
risk of hepatotoxicity (Mottaghi&Karemzade, 2005). The patient’s liver enzymes were 
significantly raised, as noted in the laboratory results. Adverse drug reactions  were  under 
reported by healthcare professionals, no ADR’s were reported during the study period. In 
addition, it was not included as an objective of the study at RCWMCH.  
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5.6 Off-label prescribing  
In the present study, off- label prescribing was not considered a bad practice. In particular, 
when benefits outweighed risks, very high doses were prescribed and where drugs were not 
readily available in paediatric formulation, adult formulations were prescribed and modified 
according to the prescriber’s instructions. 
The frequency of off-label prescribing in my study was less than 2% for any type of 
off-label prescribing. Age was the most common factor regarding OL prescribing, with other 
factors infrequently being a causal factor for OL prescribing. In a study carried out by 
Conroy, McIntyre &Choonara (1999) in the United Kingdom, it was observed that off-label 
prescribing in terms of age, that is, outside the licensed age range, was a common practice. 
Similarly, in this study conducted at RCWMCH ,age was the common reason for off-label 
prescribing. Another similarity between the present study and that of Conroy and his 
colleagues (1999) was the use of morphine in neonates. Morphine is not recommended for 
use in neonates, but was readily prescribed when deemed necessary. For certain drugs (for 
example, Ethambutol), the manufacturer does not recommend use in children aged below 
eight years, except in certain conditions, for example, in patients with extra-pulmonary TB. 
However, Ethambutol is readily prescribed (off -label), as observed in the present study at 
RCWMCH. Clonidine (an antihypertensive agent) is also readily prescribed for children, 
including neonates, although safety has not been established for children aged below 12 
years. Clonidine was found to be prescribed as part of pain and sedation protocol, a practice 
also commonly observed at RCWMCH in the study. Another drug readily prescribed in 
children aged as young as one month as part of a “bowel cocktail” is cholestyramine (a bile 
acid sequestrant). Cholestyramine is not recommended for children aged below six years. 
Parenteral gentamycin was also readily prescribed as part of the “bowel cocktail”, with the 
route of administration oral. In the present study, drugs such as gabapentin (an anti-epileptic) 
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and amiptriptyline (a tricyclic anti-depressant) were prescribed as part of pain management 
regimen, as approved by the pain management team at RCWMCH. For paediatric 
formulation, adult drug formulations were modified as per prescriber instructions, for 
example, omeprazole MUPS (multiple unit pellet system) tablets were crushed and made into 
a solution for easier administration. In some cases, especially in neonates, a drug such as 
gentamycin was not prescribed as recommended by the manufacturer, that is, a dose higher 
than the recommended dose of 2.5mg–3mg/kg/dose to be given twice daily for neonates was 
prescribed in some cases.  
Off-label prescribing, as observed in the present study, was a much less common than 
expected, with hardly any recording or monitoring of this practice occurring. Monitoring and 
recording of OL prescription is important to improve knowledge of this widely acceptable 
practice amongst prescribers at RCWMCH. The above-mentioned study by Conroy et al. 
(1999) showed OL prescribing to be a common practice in Europe. Not all OL prescribed 
drugs can be harmful; in fact, experienced prescribers (in both Conroy and the present study) 
show confidence in their practice when the need to prescribe an OL drug arises. At the same 
time, other prescribers, especially junior doctors at RCWMCH, must be well informed in 
order to make the best possible decision with regard to OL prescribing, while at the same 
time adhering to good prescribing practice, currently, not happening due to the prevailing 
trend over the years. 
 The potential and occurrence for drug interactions (DDIs) (see Tables 23 and 25 in 
Chapter 4, pages 84 and 86) and drug-disease interactions (DDiS) (see Table 27 in Chapter 4 
(on page 90) and off-label (OL) prescribing (see Table 29 in Chapter 4 of this thesis, page 
93)were lower than expected. Under-reporting by prescribers regarding outcome of such 
interactions and drug induced diseases as well as the occurrence of OL prescribing as an 
accepted norm by most, if not all, prescribers could have been a contributing factor to the low 
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numbers observed in the present study as far as DDIs, DDiS and OL prescribing is 
concerned. 
 
5.7 Determinants of risk factors for prescribing errors 
Senior doctors, especially registrars, were found in the study to be responsible for most of the 
prescribing in all the wards. Senior doctors are thus almost twice as likely to prescribe in 
error than are junior doctors (see Table 18 in Chapter 4 of this thesis, page 80).The trend of 
prescribing practice, reflected by the recurrence of prescribing errors, showed that junior 
doctors, guided by their senior counterparts in the wards, to some extent, “copied” the 
prescribing style of the latter. Prescribing guidelines as per an internal memo at RCWMCH 
(see Appendix I) were not adhered to by most of the prescribers. Also, a surprise finding was 
that more prescribing errors occurred in the specialty wards than in the general medical wards 
(see Table 17 in Chapter 4 of this thesis, page 79), considering that therapeutic intervention in 
the specialty ward requires more intense prescribing and decision-making by prescribers. In 
the context of the dynamic environment in the specialty wards, the risk of prescribing 
errors,cannot be under-estimated.  
Prescribing errors occurred more during weekdays than over weekends. In a study by Lesar, 
Briceland& Stein (1997) in New York , factors associated with prescribing errors, that is, 
determinants, included the patient’s age, with the very young also indicated as a risk factor. 
Other factors considered in the study by Lesar, Briceland& Stein (1997), included the 
following: inadequate knowledge of drug therapy; impaired renal function; drug allergy; the 
need for calculation of drug doses and specialised dosage formulation; and the nomenclature 
used in prescribing. These factors were not considered in the present study at RCWMCH but 
may well prove to be of great interest and significance regarding factors for consideration in 
future studies on prescribing errors 
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5.8 Limitations of the study 
5.8.1 Prescription chart design  
 The layout of the prescription charts in three wards, namely, B1, B2, and G1 at 
RCWMCH, as observed during this study, differed from the one used by prescribers in the 
PICU at the same hospital. The chart used in PICU had a section for the calculation of the 
amount of drug to be administered, thus enabling the prescriber to perform and show the 
calculation for the required dose, as well as providing clear instructions for the administering 
nurse regarding the correct amount of drug to be administered. The prescription chart used in 
wards B1, B2, and G1 were incomplete (that is, it contained no such section for showing the 
calculation of dose as in the chart used in PICU), thus placing the prescribers from these three 
wards at a distinct disadvantage. Moreover, the principal investigator was deprived of this 
relevant information, not shown by the prescriber due to lack of the relevant section (for dose 
calculation) on the prescription chart, thus directly or indirectly affecting relevant data, as 
evident in the results of the present study. 
 
 
 
 
5.8.2 Under-reporting and lack of documentation of drug interactions, drug-
disease interactions and off-label prescribing 
 Often, symptoms due to an underlying subtle drug interaction (DDI) or drug-disease 
interactions (DDiS) might have been misinterpreted as a new condition and treated with more 
drugs, thus the occurrence of a potential drug interaction and/or drug induced disease is 
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downplayed . Thus, only in very few cases, as per the clinical notes, could drug interactions 
and drug induced diseases be reported, affecting the outcome of the data collection in this 
study. In order for potential drug interactions and drug induced diseases to be reported, it 
would be an advantage to have potential drug interactions and drug induced diseases listed on 
a database for prescribers to access the information in the wards at the time of prescribing 
potential interacting drugs. This reporting method of clinically significant drug interactions 
and drug induced disease will be practical to implement. In the case of off label prescribing, 
no mention is made that certain drugs were used as off label. OL was, in fact, more the norm 
than the exception, with prescribers almost regarding it their exclusive right to prescribe off 
label drugs. A database listing all the drugs used off-label will assist in keeping a check on 
these drugs. In the event of an untoward reaction, knowledge of off label drugs will be an 
advantage to all future prescribers at RCWMCH. 
 
 
 5.8.3 Lack of investigators 
Unlike the study carried out by Lesar et al. (2002) in New York, which involved 
many investigators in the project and errors being detected by an automated computer system, 
the study at RCWMCH involved one principal investigator, with errors manually detected 
and discussed with the prescriber and/or the doctor on duty during ward rounds. The 
collection of the relevant data and recording of all the information regarding prescribing 
errors and so forth was the sole activity of the principal investigator.  
 
 
 
 
 
 
 
110 
 
     Chapter 6 
Conclusions and Recommendations 
6.1 Conclusions 
With an overall prescribing error rate of 72.5%, the study at RCWMCH, demonstrated that 
prescribing errors posed a risk in the medicine management chain. The different types of 
prescribing errors were likely to occur due to the writing style of the prescriber. This pertains 
to prescribing errors such as incomplete prescription (missing information); use of wrong 
drug approved name; use of abbreviations; legibility concerns; and lack of clarity, among 
others. This clearly demonstrated the lack of adherence by the prescribers to the Medicines 
and Related Substances Act 101 of 1965 (Medicines and Related Substance Act 101 of 1965, 
Regulations as amended, 2014: 28) that defines and stipulates the legal requirements for a 
correct prescription. Currently, due to limited research studies on prescribing practice 
undertaken among child patients, there exists no benchmark that can be used as a guideline to 
correct prescribing, especially in South Africa. The need to monitor and measure prescribing 
as an important tool of medicine management is of vital importance. An incomplete 
prescription constitutes an illegal medico-legal document and a problematic practice by 
prescribers in general, and should, in particular, be addressed at the RCWMCH, the site of 
this study. As per the requirement for correct prescribing (Medicines and Controlled 
Substance Act 101 of 1965 (Medicines and Related Substance Act 101 of 1965, Regulations 
as amended, 2014: 28) prescribers should exercise more responsibility in prescribing practise 
by writing complete prescriptions, that is, all relevant information about the drug in terms of 
the correct name, dose, frequency, duration, route of administration, and quantity to be 
administered. Training on prescribing guidelines should be implemented to improve 
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prescribing practice by providing the necessary skills to health care practitioners about the 
writing and handling of prescriptions.  
The present study showed no big difference in the prescribing error frequency per 
different classes of drugs, an indication that any drug was at risk for a prescribing error. 
Abbreviations, the third most frequent type of error, were mostly used for vitamins and 
minerals, the class of drugs prescribed the most, but with one of the lowest frequency of 
error, as observed in this study. In some cases, the wrong name, that is, the trade or brand 
name was used for drugs, for example, antibiotics, a class of drug frequently prescribed in 
most medical cases, with antibiotics therefore having a relatively higher frequency of 
prescribing errors compared to other classes of drugs. Dosing errors, as observed in this 
study, contributed to a low frequency of error, including the mistaken placing of an extra zero 
or naught (0) in some of the calculations, for example, for benzyl penicillin, making the 
potential for a tenfold error real. 
 The presence of potential drug interactions (DDIs) and drug-disease interactions 
(DDiS) was not easily identifiable, mostly under-reported, and difficult to predict. 
Interpretation of laboratory results assisted in identifying the outcome of drug interactions, 
for example, an increase in potassium levels was observed in some cases. The recording of 
blood pressure on the vital sign chart also served as a guideline in cases where drug 
interactions caused additive hypotensive effects. Drug-disease interactions were less likely to 
be reported in the clinical notes than were drug interactions, with concerns often raised in the 
form of a question by the prescriber. For example, Azathioprine as a causative agent for drug 
induced hepatitis? A recommendation to address this would be the use of computer database 
programs in the wards to help identify and monitor drug interactions and drug-disease 
interactions.Prescribers will then be alerted to potential drug interactions and drug-disease 
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interactions assisting prescribers in making better clinical decisions pertaining to drug 
therapy and disease state of the patient. 
 Off-label (OL) prescribing, viewed as an acceptable practice by most prescribers, is 
also under-reported. Age was certainly not a major deterrent when one considers the 
relatively high number of off label prescribing in the paediatric population in this study. The 
procurement of pharmaceuticals also has an indirect influence on off-label prescribing 
practice at paediatric hospitals such as RCWMCH. The standard treatment guidelines (STGs) 
for paediatrics, the code list of the Provincial Government of the Western Cape (PGWC), 
tenders by the National Department of Health (NDoH), the Pharmacy and Therapeutics 
Committee and the procurement policies of the PGWC all provide guidelines for the 
procurement of pharmaceuticals. These exogenous factors influence off-label prescribing and 
pose a challenge to both senior and junior prescribers, who in many instances in this study, 
were found to have no awareness even of any challenges in the procurement of 
pharmaceuticals. Not all medicines on the PGWC code list are on the NDoH tenders; NDoH 
tenders are renewed every two years and often medicines on the PGWC code list are removed 
from the tender. In addition, paediatric formulations of medicines are often not on NDoH 
tenders but incorporated in the STGs. Thus, off-label prescribing should be monitored and 
recorded more closely, especially in the very young age group, in order to minimise the risks 
associated with off-label prescribing. 
The determinants of prescribing errors included: (a) senior doctors who were 
responsible for writing up more prescriptions and consequently responsible for more 
prescribing errors, (b) prescriptions generated in the speciality wards where doctors generally 
worked under greater pressure due to the dynamic environment in these wards, (c) weekdays, 
during which most prescriptions were written up, thus the greater frequency of errors. 
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A pilot study to assess the benefit of electronic prescribing (e-prescribing) will assist 
in determining whether a shift towards e-prescribing might help to minimise prescribing 
errors. The need for a ward/clinical pharmacist to be part of the healthcare team daily ward 
rounds in all the wards can be of great benefit with respect to pharmacovigilance. The present 
study showed that many prescribing errors could have been avoided if a pharmacist was 
present during the clinical ward rounds. Thus, a study to measure the impact of a clinical 
pharmacist on prescribing practices, especially at a ward level in South African hospitals 
would be interesting. A study on the clinical intervention by pharmacists will also assist in 
analysing the different types of interventions, namely, (a) indications describing unnecessary 
medicine therapy, untreated condition, inappropriate drug, and therapeutic duplication, (b) 
effectiveness describing inappropriate dosage, and/or frequency or duration, and (c) safety 
describing adverse drug reaction, adverse drug event, and drug food interaction. 
Another important observation made in the course of the present study was 
misunderstanding shown by the administering nurse regarding an order as instructed on the 
prescription chart. An example illustrating this was the clarity of prescriptions reading 
“po/per” (per oral or per rectum) for paracetamol. An instruction such as this left the 
administering nurse with a certain degree of uncertainty as to the formulation to be 
administered to the patient. A study on administration of medicines as part of medicine 
management use would also make for an interesting research project aimed at showing the 
clinical significance of potential administration errors due to incorrect prescribing 
instructions and misinterpretations. 
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6.2 Recommendations 
In order to minimise the risk of prescribing errors, potential drug interactions (DDIs), 
potential drug-disease interactions (DDiS), and off-label (OL) prescribing, the following 
recommendations should be considered: 
 Educating all prescribers via tutorials or training workshops on a regular basis will be 
beneficial in the future and translate into better patient health outcomes in alignment 
with two of the health objectives of the National Drug Policy (NDP), that is, (a) 
ensuring good prescribing practices and (b) promoting the rational use of medicines 
by prescribers through provision of necessary training, education, and information;  
 There should be standardisation of the triaging system from the point of entry when a 
patient is admitted to a ward where a new prescription chart is generated right up to 
the point of the patient being discharged; 
  Standardisation of prescription charts in all the wards at RCWMCH to allow for 
provision of complete information required,as per the prescribing guidelines described 
in the Medicines and Related Substances Act 101 of 1965 (Medicines and Related 
Substance act 101 of 1965, Regulations as amended, 2014: 28) including a section 
showing the amount of drug to be administered by the administering nurse;  
 Prescriptions with abbreviations and wrong names should be referred for rectification 
by the prescriber on duty and calculations checked by a pharmacist on ward rounds 
prior to the drug being administered to the patient;  
 The use of computer database programs in wards to help identify and monitor drug 
interactions (DDIs) and drug-disease interactions (DDiS). Prescribers will then be 
alerted to potential drug interactions and drug-disease interactions, which will assist 
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them in making informed clinical decisions with regard to drug therapy and disease 
state of the patient; 
 Implementation of optimal alignment of the various policies (see the earlier section on 
conclusions in this chapter) affecting rational prescribing in children with regard to 
off-label (OL) prescribing;  
 Reporting of prescribing errors should be the responsibility of all healthcare 
professionals involved in the medication management system in order to measure and 
improve the practice of prescribing; 
 The undertaking of further research to optimise the prescribing chart and to determine 
the effect of an improved prescription chart on prescribing practice. In addition, the 
frequency of known drug interactions (DDIs), drug-disease interactions (DDiS) and, 
consequently, adverse drug reactions (ADRs) require further study, especially in a 
hospital setting such as the RCWMCH where patients are known to have co-morbid 
conditions and are subjected to poly-pharmacy practice;  
 There is also a need to include a pharmacist as part of the multidisciplinary healthcare 
team, especially with regard to pharmacovigilance. Pharmacists could act in an 
advisory capacity at ward level with regards to rational prescribing. Their 
involvement in generating correct prescriptions will minimise risk to patient health 
outcomes. The pharmacist’s role in drug utilisation review cannot be underestimated 
in this regard.  
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Appendix A 
Data collection sheet 1 
Title : Prescribing practice  at  a Tertiary level paediatric hospital in South Africa 
 
Biographical information 
Study number 
 
Folder number 
 
Time of assessment of prescription chart in relation 
to admission date 
Day 3-5 Day 7-10 
Date of birth (dd/mm/yyyy) 
 
Gender Female Male 
Date of admission (dd/mm/yyyy) 
 
Mass (kg) Length (cm) BSA (m
2
) 
 
Clinical Information 
Ward location B1 B2 ICU G1 
Current date 
(dd/mm/yy)  
 
Primary Diagnosis  
Co-morbid 
conditions 
 
Current Drugs Prescribed 
Drug 
 no. 
Name  
of  
drug 
Class 
 of 
 drug 
Job 
 title   
of Dr. Strength Formulation Dose Route Frequency Duration  Quantity 
Formulary  
status 
Day  
of the  
week 
                          
                          
                          
                          
                          
 
 
 
 
128 
 
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
             
PRESCRIBING ERROR 
Drug 
no. 
Description of error Type of error 
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Potential Drug – Drug Interaction ( DDI ) 
Drug 
no. 
Description of potential DDI Type of DDI 
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Potential Drug – induced diseases 
Drug 
No. 
Description of DDisI Type of DDisI 
   
   
   
   
   
   
Off – Label Prescribing ( OL ) 
Drug 
no. 
Description of OL Type of OL 
   
   
   
   
 
Class of drug 
(1) Gastrointestinal;  (2)Blood System;   (3)Cardiovascular;    
(4)Hormonal;   (5) Anti-Infective agent;  (6) Oncology;   
(7)Musculo-skeletal;  (8) Nervous system;   
(9) respiratory System;  (10)other    
 
Classification of prescribing errors 
(1)Incomplete information; (2) Legibility; (3) Clarity;  
(4) Abbreviations; (5) Wrong drug approved name;  
(6) Dose too high;   (7) Dose too low; (8) Allergy;  
(9) Wrong time; (10) Wrong route; (11) Wrong frequency;  
(12) Wrong unit; (13) Duplication (14) Alteration;  
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(15) Contraindication; (16) Other   
 
Classification of potential drug-drug interaction 
(1)Increase in absorption; (2) Decrease in absorption;  
(3) Increase in drug distribution; (4) Decrease in drug distribution;    
(5) Increase in metabolism; (6) Decrease in metabolism;  
(7) Increase in excretion; (8) Decrease in excretion; (9) Other 
 
Classification of potential drug-disease interaction 
(1)Cardiotoxicity; (2) Nephrotoxicity; (3) Hepatotoxicity; (4) Ototoxicity;  
(5) Blood disorders; (6) Change in glucose levels; (7) Other 
 
Classification of off-label prescribing 
(1)Age; (2) Formulation; (3) Dose; (4) Frequency; (5) Route;  
(6) Duration; (7) Other 
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Appendix B 
Data collection sheet 2 
Possible determinants/predictors of prescribing errors 
       
 
1. Level of qualification of 
prescriber 
  
5. Drug formulation 
  
 
Intern  1 
 
IV  1 
 
 
SHO  2 
 
IM  2 
 
 
Registrar  3 
 
Oral  3 
 
 
Consultant  4 
 
Suppository  4 
 
    
Inhalation  5 
 
 
2. Day of the week item 
prescribed 
  
Tppical  6 
 
 
Monday  1 
 
Other  7 
 
 
Tuesday  2 
    
 
Wednesday  3  6. Class of drug 
   
 
Thursday  4 
 
Gastrointestinal tract 
 1 
 
 
Friday  5 
 
Blood system 
 2 
 
 
Saturday  6 
 
Cardiovascular 
 3 
 
 
Sunday  7 
 
Hormonal 
 4 
 
    
Anti-Infective agent  5 
 
 
3. Age of the patient ( in 
years) 
  
Oncology 
 6 
 
 
0-2  1 
 
Musculo-skeletal 
 7 
 
 
3-5  2 
 
Nervous system 
 8 
 
 
6-10  3 
 
Respiratory system 
 9 
 
 
>10  4 
 
Other 
 10 
 
       
 
4. Location (ward) 
  
7. No. of drugs prescribed 
  
 
PICU  1 
 
1-4 
 1 
 
 
G1 (Oncology)  2 
 
5-10 
 2 
 
 
B1 (Medical)  3 
 
>10  3 
 
 
B2 (Medical)  4 
    
    
8. Formulary status of drug 
  
    
Formulary  1 
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Appendix C 
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Appendix D 
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Appendix E 
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Appendix F 
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Appendix G 
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Appendix H 
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Appendix J 
 
MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965  
(Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 
94, Gazette No. 1413]  
GENERAL REGULATIONS MADE IN TERMS OF THE MEDICINES AND RELATED SUBSTANCES 
ACT 101 OF 1965, AS AMENDED  
Government Notice R510 in Government Gazette 24727 dated 10 April 2003. Commencement date: 
2 May 2003 (see regulation 50).  
As amended by:  
Government Notice R1506 in Government Gazette 25593 dated 16 October 2003. Commencement 
date: 16 October 2003. Correction Notice – Government Notice 1565 in Government Gazette 25622 
dated 31 October 2003.  
Government Notice R389 in Government Gazette 33177 dated 12 May 2010. Commencement date: 
12 May 2010.  
Government Notice R766 in Government Gazette 36929 dated 14 October 2013. Commencement 
date: 14 October 2013.  
Government Notice R870 in Government Gazette 37032 dated 15 November 2013. Commencement 
date: 15 November 2013 (except for the amendments addressing complementary medicines as per 
regulations 8, 9, 10, 40 and 48 of the General Regulations).  
Government Notice R870 in Government Gazette 37032 dated 15 November 2013. Commencement 
date of the amendments addressing complementary medicines as per regulations 8, 9, 10, 40 and 48 
of the General Regulations: 15 February 2014. 
28. PARTICULARS WHICH MUST APPEAR ON A PRESCRIPTION OR ORDER FOR A MEDICINE  
(1) Every prescription or order for a medicine must be written in legible print, typewritten or computer 
generated and signed in person by a medical practitioner, dentist, veterinarian or authorised 
prescriber or in the case of an order, an authorised person, and must at least state the following:  
(a) the name, qualification, practice number and address of the prescriber or authorised person 
placing the order;  
(b) the name and address of the patient in the case of a prescription or the name and address of the 
person to whom the medicines are delivered in the case of a prescription issued by a veterinarian;  
(c) the date of issue of the prescription or order;  
(d) the approved name or the proprietary name of the medicine;  
(e) the dosage form;  
(f) the strength of the dosage form and the quantity of the medicine to be supplied: Provided that in 
the case of Schedule 6 substances the quantity to be supplied shall be expressed in figures as well as 
in words: Provided further that where the prescriber has failed to express the quantity in figures as 
well as in words, the medical practitioner, dentist, veterinarian or pharmacist dispensing the medicine 
may, after obtaining confirmation from the prescriber, insert the words or figures that have been 
omitted;  
(Regulation 28(1)(f) substituted by regulation 17 of Government Notice R870 in Government Gazette 
37032 dated 15 November 2013)  
(g) in the case of a prescription, instructions for the administration of the dosage, frequency of 
administration and the withdrawal period in the case of veterinary medicines for food producing 
animals;  
(h) the age and sex of the patient and in the case of veterinary medicine, the animal species; and  
(i) the number of times the prescription may be repeated. 
 
 
 
 
 
 
